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CHAPTER I 
 
STATEMENT OF DISSERTATION 
 
 This dissertation describes advances in total synthesis, synthetic 
methodology, and chemical biology.  The total synthesis and stereochemical 
revision of Ciliatamides A-C will be discussed in detail.  In addition, the total 
synthesis of 8-epi-Lucentamycin A will be described.  Lastly discussed is the 
development of microwave methodology to improve the synthesis of 
pyrazolo[1,5-a]pyrimidines.  This new methodology was used to rapidly optimize 
a lead pyrazolo[1,5-a]pyrimidine screening hit into a highly selective and potent 
bone morphogenetic protein (BMP) inhibitor as well as selective KDR inhibitors 
using zebrafish as an in vivo screening tool. 
 Within the Ciliatamide project, the chemistry to synthesize the Ciliatamides 
A-C was a collaborative effort with Dr. Jana Lewis performing some of the 
reactions while I performed the others.  Dr. Lewis also synthesized the library of 
analogs, as I worked out the conditions to reduce epimerization in the synthesis 
of the Ciliatamide C stereoisomers.  I also performed all of the spectroscopic 
analysis and data collection for the NMRs and optical rotations. 
 The synthesis of the 8-epi-Lucentamycin A was a collaborative project 
with the Sulikowski group.  I performed all initial model system studies and 
developed the route to avoid epimerization while coupling the northern and 
southern portions of the molecule.  A postdoc in the Sulikowski group, Dr. Bruce 
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Meloncon, with an undergraduate summer student Emily Wang, developed the 
titanocene chemistry and the route to the proline core.  Due to protecting group 
incompatibilities, I took that basic approach and developed an entirely new 
sequence which led to the synthesis of 8-epi-Lucentamycin A.  The biological 
evaluation of the model system and 8-epi-Lucentamycin A was performed by 
Brenda Crews from the laboratory of Dr. Larry Marnett. 
 For the project involving the development of microwave methodology and 
synthesis of BMP inhibitors, I developed all of the microwave chemistry and 
optimized the conditions to make the first generation libraries which led to the 
identification of the isopropoxy ether in combination with the pyridine.  Further 
work, by a colleague in the group, elaborated the pyridine to the quinoline, which 
led to the first selective, potent BMP inhibitor.  All of the biological testing was 
done by our collaborators in the laboratory of Dr. Charles Hong. 
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CHAPTER II 
 
TOTAL SYNTHESIS AND STEREOCHEMICAL 
REVISION OF CILIATAMIDES A-C 
 
Background and Retrosynthesis 
Leishmaniasis is a group of vector-borne diseases, caused by obligate 
intra-macrophage parasites of the genus Leishmania, which is endemic in the 
tropics, subtropics, and the Mediterranean basin.1,2  The disease may manifest 
itself as a cutaneous, mucosal, dermal, or visceral variant.  With visceral 
leishmaniasis (VL) being the most deadly.  Among parasitic diseases 
leishmaniasis’ death toll is second only to malaria, afflicting more than 12 million 
people in 88 countries with an annual death toll exceeding 50,000.  Some severe 
VL epidemics have been reported.  Between 1984 and 1994 in Southern Sudan, 
VL killed an estimated 100,000 people out of a population of 280,000, though this 
number was made worse by civil war and famine.  VL has its greatest effect on 
poor communities, generally in remote rural areas, and pushes patients and 
families further into poverty because of the high direct and indirect costs.  
VL is a systemic disease that is deadly if left untreated.  Because of the 
high disease cost and the low standard of living of most infected individuals, 
symptoms often persist for weeks to months before the patient either seeks 
medical attention or dies.3  Untreated VL patients also act as a reservoir for the 
parasites and contribute to the spread of the disease.  The current treatments for 
leishmaniasis are the pentavalent antimonials Pentostam (1) and Glucantime (2), 
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Humatin (3), Fungizone (4), Pentamidine (5) and Impavido (6) (Figure 1).  All of 
the current drugs have one or more significant drawbacks including cardiotoxic 
effects, parenteral administration, teratogenic effects, hypokalemia, 
nephrotoxicity, first-dose anaphylaxis, long treatment regimens, and prohibitively 
high cost.1-3  Patient popluations with signs of severe malnutrition and/or 
advanced disease are at increased rate of death from treatment.  Patients under 
the age of 2 or over the age of 45 are also at increased risk.3 
 
 
Figure 1.  Structures of current antileishmanial treatments 
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In 2008, Nakao and co-workers reported on the isolation of three 
lipopeptides, Ciliatamides A (7), B (8) and C (9), from the deep sea sponge 
Aaptos ciliata as the (S,S)-enantiomers (Scheme 1).4  Their structure were 
elucidated by a combination of chemical and spectroscopic methods. 
For Ciliatamide A (7) interpretation of the data from the 1H NMR, 13C 
NMR, HSQC, COSY, and HMBC led to the determination of the presence and 
connectivity of deca-9-enoic acid, N-methylphenylalanine, and lysine.  From the 
HMBC correlations it was determined that the lysine was, in fact, an ε-
caprolactam moiety.  This was confirmed by the comparison of the 1H NMR data 
of 7 with those of α-acetoamide-ε-caprolactam and acetyl lysine prepared from α-
amino-ε-caprolactam and lysine, respectively.  Ciliatamide A (7) then underwent 
chemical degradation by being dissolved in 6M hydrochloric acid, which was then 
heated to 100 ºC overnight.  By Marfey’s analysis of the acid hydrolysates it was 
determined that both the N-methylphenylalanine and lysine were of the L-
configurations.  Thus, 7 was assigned the S,S configuration. 
By comparing the NMR spectra of 7 and 8, as well as, 2D NMR data to 
determine the fatty acid was octanoic acid for 8 in comparison to deca-9-enoic 
acid for 7 the planner structure of 8 was assigned.  Again the assignment of the 
S,S absolute configuration was performed by Marfey’s analysis of the acid 
hydrolysates. 
The NMR data of 9 were similar to that of 7 and 8; however, the 
fragmentation pattern of 9, seen on the ESIMS indicated the presence of a 
cyclized orithine functionality, not the cyclized lysine as seen with 7 and 8.  This 
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was confirmed by HMBC data.  Once more Marfey’s analysis was used to assign 
the absolute stereochemistry as S,S to give the reported structure of 9. 
Importantly, Ciliatamides A and B demonstrated significant antileishmanial 
activity, and thus appeared as ideal targets for total synthesis and further 
biological evaluation, as 7-9 are chemically far less complex than current 
antileishmanials 1-6.1-4  The retro-synthesis of 7-9 (Scheme 1), involved 
cleavage of the two amide bonds to provide the (S)-3-aminoazepan-2-one (10) 
(for 7 and 8) or the (S)-3-aminopiperid-2-one (11) (for 9), L-N-methyl 
phenylalanine (12) and either decenoic acid (13) (for 7 and 9) or octanoyl 
chloride (14) (for 8).  Fortunately, all of the requisite precursors were 
commercially available. 
 
 
Scheme 1.  Structures of Ciliatamides A (7), B (8), C (9) and Retrosynthesis 
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Synthesis of S,S Isomers of Ciliatamides A-C 
 To begin the synthesis, Boc protected L-N-methyl phenylalanine (15) was 
coupled to 10 with PS-DCC and HOBt, followed by treatment with HCl in dioxane 
to deliver the free base (19) in 59% yield for the two steps after ion-exchange 
chromatography.  Peptide 19 then underwent a second amide coupling with 13 to 
afford Ciliatamides A (7), or coupling with fatty acid 14 to afford Ciliatamide B (8) 
in 56% and 58% yields, respectively.  Following the same scheme (Scheme 2), 
but substituting (S)-3-aminopiperid-2-one (11) for 10, provided Ciliatamide C (9) 
in 44% over the three steps.   The overall yields were lower than anticipated due 
to the physiochemical properties of 7-9, and poor chromatographic performance 
of these lipopeptides.  Despite these complications, the NMR spectra obtained 
were in complete accord with those reported by Nakao and co-workers; however, 
the original spectra were recorded under very dilute conditions to minimize 
conformer populations.4 
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Scheme 2.  Synthesis of Ciliatamides A (7), B (8), C (9) 
 
 Based on these results, we then explored a solution phase parallel 
synthesis approach for the synthesis of Ciliatmides A (7) and C (9) employing 
only polymer-supported reagents, scavengers, and ion-exchange 
chromatography to avoid either normal or reverse-phase chromatography.5 This 
strategy afforded improved results, providing 7 and 9 in overall yields in excess 
of 75% for the three steps with >95% purity (Scheme 3). 
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Scheme 3.  Solution Phase Parallel Synthesis of Ciliatamides A (7), C (9) 
 
Synthesis of Analog Library 
 Due to the expedited route to 7-9, in parallel, we prepared a 42-member 
solution phase library of unnatural Ciliatimide analogs 20a-n, 21a-n, and 22a-n. 
The library employed three scaffolds 18, 19, and the unnatural (R,S) congener of 
19, and a collection of 14 different acid chlorides (Figure 2). All final compounds, 
including additional copies of 7-9 were purifed to >98% by mass-directed 
preparative HPLC and afforded yields ranging from <5% to 60% for the three 
steps; however, we obtained sufficient quantities for biological evaluation in every 
case.6 
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Figure 2.  Three by 14 library of unnatural Ciliatamide analogs 
 
Discrepancy of Optical Rotation and Synthesis of all Possible Isomers 
 As we were compiling the final characterization data for 7-9, a discrepancy 
was noted with respect to the reported optical rotations, [α]D
20 = +40 (c = 0.05, 
MeOH), [α]D
20 = +55 (c = 0.1, MeOH), [α]D
26 = +74 (c = 0.1, MeOH) for the 
natural products 7-9, respectively.4   While the 1H and 13C NMR spectra of our 
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synthetic 7-9 overlayed with the natural products, the optical rotations were of 
comparable magnitude, but opposite sign, that is, [α]D
20 = -35 (c = 0.05, MeOH), 
[α]D
20 = -44 (c = 0.1, MeOH), [α]D
20 = -43 (c = 0.1, MeOH) for synthetic 7-9, 
respectively.   On the basis of these results, we synthesized the four possible 
stereoisomers ((S,S), (S,R), (R,S) and (R,R)) of Ciliatamide A and Ciliatamide B, 
employing the route depicted in Scheme 2, and compared NMR spectra and 
optical rotations to the reported values (Figure 3).  For Ciliatamide A (7),  
reported to be the (S,S)-enantiomer, the NMRs of diastereomeric pairs 23 (S,R) 
and 24 (R,S), as anticipated, did not match 7; however, the (R,R)-enantiomer of 
Ciliatamide A (25) was in complete accord with the published spectral data and 
possessed an optical rotation ([α]D
20 = +42 (c = 0.05, MeOH)) that matched the 
literature report as well.   Similarly, the (R,R)-enantiomer of Ciliatamide B (28) 
overlayed with the reported NMR spectra of 8 as well as provided optical 
rotations in agreement with those reported by Nakao and co-workers, ([α]D
20 = 
+49 (c = 0.1, MeOH)) for 28. 
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Figure 3.  Library of all possible stereoisomers of Ciliatamides A-C and all the 
corresponding optical rotations 
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 Attempts to prepare the (S,R), (R,S) and (R,R) steroisomers of Ciliatamide 
C following the route depicted in Scheme 2 led to significant racemization of the 
(R)-piperidin-2-one, which was not observed within the Ciliatamide A and B 
series or the (S)-piperdin-2-one (11).  Therefore, after several approaches, we 
developed an alternate route that avoided racemization and afforded pure 
stereoisomers (Scheme 4).  In this instance, the carbodimide coupling in 
Scheme 2 was replaced with a HATU/collidine system for the coupling of pure 
(S)- or (R)-piperidin-2-one, (11) and (29),respectively, with either enantiopure  
Boc-L-N-MePhe (15) or Boc-D-N-MePhe (30). The milder acidolysis of the Boc 
deprotection of 31-33 with 5-7% TFA in CH2Cl2 in an ice bath instead of 10 
equivalents of HCl was used to deliver isomers 34-36.   Finally, a second HATU 
coupling with decenoic acid provided the remaining stereoisomers of Ciliatamide 
C  37 (S,R), 38 (R,S) and 39 (R,R).  As in the case of Ciliatamides A and B, both 
NMR spectra and optical rotation ([α]D
20 = +56 (c = 0.1, MeOH)) for 39 confirm a 
stereochemical reassignment of the natural product to the (R,R)-enantiomer. 
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Scheme 4.  Synthesis of the (S,R), (R,S) and (S,S)-stereosiomers of Ciliatamide 
C, 37, 38 and 39, respectively 
 
 
 For Ciliatamides A-C, the optical rotations were positive, and in agreement 
with the literature report, only when the unnatural D-MePhe was employed.  
Nakao and co-workers utilized Marfey’s analysis7 to establish the L-configuration 
of the caprolactams and the MePhe in 7-9; however, the data presented herein 
suggests that either the reported optical rotations were incorrect, or the 
stereochemical assignments were incorrect.4  It is also possible that the natural 
products, under the forcing acidic conditions of the Marfey’s analysis racemized.  
When Marfey’s analysis is employed to determine the absolute stereochemistry 
of amino acids, harsh acidic conditions are used to degrade the natural product 
into the amino acid segments.  These amino acids then undergo a SNAr reaction 
with the L or D enantiomer of fluoro dinitrophenyl-alaninamide (FDAA).  The 
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corresponding products are then eluted through a HPLC column and their 
retention times are compared to the retention times of standards, which have 
been prepared from the L or D enantiomers of the corresponding amino acids. 
The method of chemical degradation used to determine the absolute 
stereochemistry of the Ciliatamides was to dissolve the natural products in 6M 
hydrochloric acid, which was then heated to 100 ºC overnight.  It is a logical 
possibility that the amino acids racemizied during acid hydrolosis as our 
observations showed that the (R,R)-analogs are prone to acid catalyzed 
racemization to the (S,S)-enantiomers.  Thus, based on our data, we proposed a 
stereochemical revision for Ciliatimides A-C from the (S,S)-7, 8, and 9 to the 
(R,R)-25, 28, and 39 (Figure 4). 
 
 
Figure 4.  Revised structures of the natural lipopeptides Ciliatimides A-C after 
stereochemical revision 
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Conclusions 
 In summary, we have completed the first total synthesis of Ciliatamides A-
C, originally reported as the (S,S)-enantiomers 7-9, employing both traditional 
organic synthesis and solution phase parallel synthesis.   Based on spectral and 
optical rotation data for all the possible stereoisomers of 7-9, we proposed a 
stereochemical revision for Ciliatamides A-C to the (R,R)-enantiomers 25, 28 and 
39, respectively.  Due to the expedited route, we also prepared a library of 42 
unnatural Ciliatamide analogs 20a-n, 21a-n, and 22a-n, that when combined with 
the unnatural stereoisomers, exceeds 50 unnatural analogs. 
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Experimental Section 
General.  Unless otherwise noted, starting materials were obtained from 
commercial suppliers and used without further purification.  1H/13C NMR spectra 
were recorded on a Bruker 600 MHz AV-NMR spectrometer located in the Small 
Molecule NMR Facility at Vanderbilt University.  Minor conformer signals 
attributed by Nakao and co-workers to conformers around the N-methyl amide 
bond between MePhe residues and fatty acids were also observed4 however, 
since chemical shifts for both sets of conformers were not observed for all shifts, 
only major conformer signals are reported below.  Electrospray atmospheric 
pressure ionization (ES-API) liquid chromatography/mass spectrometry (LCMS) 
was performed on an Agilent Technologies 6130 Quadrupole, and the data were 
analyzed using LC/MSD ChemStation software.  As described by Nakao and co-
workers, a fragment ion peak was observed in the ES-MS corresponding to 
cleavage at the amide bond closest to the lactam.  The compounds were purified 
by preparative LCMS to >98% purity unless otherwise noted.  A Micromass Q-
TOF API-US mass spectrometer was used to acquire high-resolution mass 
spectrometry (HRMS) data.  The HRMS results were obtained with ES as the ion 
source and leucine enkephalin as the reference.   
General procedure for amide coupling A.  Carboxylic acid (1.5 equiv), 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 2.0 equiv), 1-
hydroxybenzotriazole (HOBt, 3.0 equiv), and DIPEA (2.0 equiv) were added to a 
solution of amine (1.0 equiv) in anhydrous DMF (23 mM).  The mixture was 
stirred at room temperature overnight.   
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General procedure for amide coupling B.  To a solution of amine (1.0 equiv) in 
anhydrous DMF (23 mM) in a 5 mL microwave reaction vial were added acid 
chloride (3.0 equiv), NMM (3.6 equiv), and a catalytic amount of DMAP.  The vial 
was heated in a microwave synthesizer to 160 °C for 15 min.   
General procedure for amide coupling C.  Carboxylic acid (1.5 equiv), N- 
cyclohexylcarbodiimide-N’-propyloxymethyl polystyrene (PS-DCC, 2.0 equiv), 
and HOBt (1.7 equiv) were suspended in CH2Cl2 (65 mM amine) and mixed for at 
least 10 min prior to the addition of amine (1.0 equiv).  The mixture was agitated 
at room temperature overnight.  After the reaction, the HOBt was scavenged 
using macroporous triethylammonium methylpolystyrene carbonate (MP-
carbonate, 5 equiv) for at least 2 h at room temperature prior to filtration. 
General procedure for amide coupling D.  O-(7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU, 1.5 equiv) was added to a 
flame dried flask under argon and evacuated and filled with argon (3x).  Solutions 
of amine (1.0 equiv) and carboxylic acid (1.0 equiv) and in anhydrous DMF (0.3 
M) were then added.  An equal volume of anhydrous CH2Cl2 was added to the 
flask before adding collidine (2.0 equiv).  The mixture was stirred at room 
temperature for 4 h.  HCl (1 N) was added to neutralize the reaction, diluted with 
CH2Cl2 and washed with water (3x).  The solution was then concentrated in 
vacuo to yield the crude product. 
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tert-butyl methyl((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)carbamate (16).  Boc-N-methyl-L-phenylalanine (15, 668 mg, 2.39 mmol) was 
dissolved in about 3 mL of DMF.  30 mL of dry CH2Cl2 was added to the mixture 
along with PS-DCC (3.187 g, 3.98 mmol), and the resin was allowed to swell for 
10 min at room temperature with agitation.  HOBt (404 mg, 2.99 mmol) was 
added with agitation for 10 min followed by the addition of a suspension of (S)-3-
aminopiperid-2-one HCl (11, 300 mg, 1.99 mmol) in a mixture of 1 mL DMF, 1 
mL MeOH, and 9 mL CH2Cl2.  The mixture was agitated overnight at room 
temperature.  The resin was removed by filtration through a pad of Celite 
followed by rinsing with CH2Cl2.  The organics layer was washed with 2 × 25 mL 
of 1 N HCl, dried over sodium sulfate, and concentrated by rotary evaporation to 
yield pale yellow oil.  LCMS, single peak, 2.782 min, ES-API: m/z 376.2 [M+H]+.   
 
 
 
tert-butyl methyl((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)carbamate (17).  17 was synthesized by the procedure used for 16 starting 
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from Boc-N-methyl-L-phenylalanine (15, 1.339 g, 4.79 mmol) and (S)-3-
aminoazepan-2-one (10, 512 mg, 3.99 mmol) to yield a pale yellow oil.  LCMS, 
single peak, 2.998 min, ES-API: m/z 390.3 [M+H]+. 
 
 
 
N-(S)-piperid-2-one-3-yl-(S)-2-methylamino-3-phenylpropanamide (18).  16 
(748 mg, 1.99 mmol) was dissolved in 43 mL of dichloroethane, and 5 mL of 4 M 
HCl in dioxane was added to the stirring solution.  One mL of MeOH was added 
to the mixture to keep reagents and products solubilized.  The mixture was 
stirred overnight at room temperature.  The reaction mixture was concentrated by 
rotary evaporation to yield a yellow solution, which was taken up in CH2Cl2 and 
loaded onto a Varian Bond Elut 10 g SCX cartridge.  The cartridge was washed 
with 25 mL each of CH2Cl2 then MeOH and was then eluted with 2 M NH3 in 
MeOH, and these elution fractions were concentrated by rotary evaporation to a 
yellow oil.  2-step yield: 76% (418 mg).  [α]D
20 +12 (c 0.25, MeOH); Rf 0.16 (9:1 
DCM/MeOH); IR (neat) 3281, 3225, 2921, 2866, 1644, 1552, 1492, 1325 cm-1; 
1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.25 (m, 5H), 4.11 (dd, J = 10.6, 5.9 Hz, 
1H), 3.51 (dd, J = 7.6, 5.9 Hz, 1H), 3.44 (t, J = 6.8 Hz, 1H), 3.27 (m, 2H), 3.04 
(dd, J = 13.7, 6.5 Hz, 1H), 2.91 (dd, J = 13.7, 7.0 Hz, 1H), 2.39 (s, 3H), 1.98 (m, 
1H), 1.89 (m, 1H), 1.82 (m, 1H), 1.76 (qd, J = 11.7, 3.4 Hz, 1H); 13C NMR 
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(CD3OD, 150 MHz, 25 °C): δ 173.8, 172.4, 137.8, 130.5, 129.6, 128.0, 66.0, 
51.2, 42.7, 39.7, 34.3, 28.5, 22.4; LCMS, single peak, 1.743 min, ES-API: m/z 
276.2 [M+H]+; HRMS (TOF, ES+) C15H21N3O2Na [M+Na]
+ calc'd 298.1531, found 
298.1526. 
 
 
 
N-(S)-azepan-2-one-3-yl-(S)-2-methylamino-3-phenylpropanamide (19).  19 
was synthesized by the procedure used for 18 starting from 17 (1.556 g, 3.99 
mmol) to yield a colorless oil.  2-step yield: 59% (685 mg).  [α]D
20 -18 (c 0.25, 
MeOH); Rf 0.32 (9:1 DCM/MeOH); IR (neat) 3318, 2931, 2855, 1653, 1508, 
1478, 1435 cm-1;  1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.27 (t, J = 7.4 Hz, 2H), 
7.21 (m, 3H), 4.49 (dd, J = 11.2, 1.6 Hz, 1H), 3.27 (m, 2H), 3.19 (bdd, J = 15.2, 
4.2 Hz, 1H), 3.01 (dd, J = 13.7, 5.6 Hz, 1H), 2.80 (dd, J = 11.4, 7.8 Hz, 1H), 2.29 
(s, 3H), 1.97 (dt, J = 14.0, 3.5 Hz, 1H), 1.84 (m, 3H), 1.45 (qd, J = 12.8, 2.8 Hz, 
1H), 1.35 (m, 1H); 13C NMR (CD3OD, 150 MHz, 25 °C): δ 176.8, 174.9, 138.7, 
130.3, 129.5, 127.8, 67.0, 53.0, 42.5, 40.4, 35.1, 32.7, 29.9, 29.0; LCMS, single 
peak, 1.735 min, ES-API: m/z 290.2 [M+H]+; HRMS (TOF, ES+) C16H23N3O2Na 
[M+Na]+ calc'd 312.1688, found 312.1693. 
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N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (S,S)-Ciliatamide A (7 or 21a).  Amide coupling according to general 
procedure A starting from amine 19 (100 mg, 0.35 mmol), 9-decenoic acid (13, 
88 mg, 96 μL, 0.52 mmol), EDC (132 mg, 0.69 mmol), HOBt (140 mg, 1.04 
mmol), and DIPEA (89 mg, 120 μL, 0.69 mmol) led to the formation of the 
desired product 7 as a pale yellow oil.  Yield: 56%.  [α]D
20 –35 (c 0.05, MeOH); Rf 
0.46 (9:1 DCM/MeOH); IR (neat) 3286, 2926, 2854, 1655, 1479, 1289 cm-1; 1H 
NMR (CD3OD, 600 MHz, 25 °C): δ 7.72 (bd, J = 8.3 Hz, 1H, NH), 7.45 (t, J = 7.4 
Hz, 1H, NH), 7.22 (m, 4H), 7.17 (t, J = 7.0 Hz, 1H), 5.80 (ddt, J = 17.1, 10.2, 6.7 
Hz, 1H), 5.37 (dd, J = 11.1, 5.4 Hz, 1H), 4.97 (dd,  J = 17.1, 1.2 Hz, 1H), 4.91 (dt,  
J = 10.2, 1.2 Hz, 1H), 4.53 (dd,  J = 11.2, 1.6 Hz, 1H), 3.33 (dd, J = 14.4, 5.4 Hz, 
1H), 3.22 (bdd, J = 14.1, 2.9 Hz, 2H), 3.04 (dd, J = 14.4, 11.1 Hz, 1H), 2.90 (s, 
3H), 2.23 (t, J = 7.4 Hz, 2H), 2.03 (q, J = 6.7 Hz, 2H), 2.00 (m, 1H), 1.93 (m, 1H), 
1.82 (m, 1H), 1.79 (m, 1H), 1.62 (m, 1H), 1.51 (qd, J = 14.1, 2.9 Hz, 1H), 1.37 (m, 
2H), 1.34 (m, 2H), 1.28 (m, 2H), 1.24 (m, 2H), 1.16 (m, 2H); 13C NMR (CD3OD, 
150 MHz, 25 °C): δ 176.9, 176.7, 171.6, 140.1, 138.8, 130.0, 129.5, 127.7, 
114.7, 59.7, 53.5, 42.5, 35.1, 34.9, 34.4, 33.1, 32.2, 30.8, 30.3, 30.2, 30.0, 29.9, 
29.1, 26.1; LCMS, single peak, 3.527 min, ES-API: m/z 905.5 [M2+Na]
+; HRMS 
(TOF, ES+) C26H39N3O3Na [M+Na]
+ calc'd 464.2889, found 464.2906. 
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N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)octanamide, (S,S)-Ciliatamide B (8 or 21b).  8 was synthesized according to 
the general procedure for amide coupling B starting from amine 19 (100 mg, 0.35 
mmol), octanoyl chloride (14, 169 mg, 178 μL, 1.04 mmol), NMM (126 mg, 137 
μL, 1.24 mmol), and a catalytic amount of DMAP to yield a pale yellow oil.  Yield: 
58% (83.6 mg).  [α]D
20 –44 (c 0.10, MeOH); Rf  0.44 (9:1 DCM/MeOH); IR (neat) 
3286, 2928, 2855, 1656, 1479, 1288 cm-1; 1H NMR (CD3CN, 600 MHz, 25 °C): δ 
7.20 (m, 5H), 7.10 (bd, J = 5.8 Hz, 1H, NH), 6.45 (bs, 1H, NH), 5.37 (dd, J = 
10.5, 5.5 Hz, 1H), 4.40 (ddd,  J = 11.0, 6.2, 1.4 Hz, 1H), 3.22 (dd, J = 14.5, 5.5 
Hz, 1H), 3.16 (m, 2H), 2.91 (dd, J = 14.5, 10.5 Hz, 1H), 2.82 (s, 3H), 2.18 (m, 
2H), 1.97 (m, 1H), 1.89 (m, 2H), 1.77 (m, 1H), 1.70 (m, 1H), 1.37 (quintet, J = 7.4 
Hz, 2H), 1.32 (m, 1H), 1.26 (m, 2H), 1.21 (m, 4H), 1.14 (m, 2H), 0.87 (t, J = 7.2, 
3H); 13C NMR (CD3CN, 150 MHz, 25 °C): δ 175.5, 174.9, 169.9, 139.2, 129.9, 
129.2, 127.3, 58.2, 53.0, 42.1, 34.2, 33.9, 32.45, 32.39, 31.9, 29.80, 29.78, 29.7, 
28.8, 25.8, 23.3, 14.4; LCMS, single peak, 3.380 min, ES-API: m/z 853.5 
[M2+Na]
+; HRMS (TOF, ES+) C24H37N3O3Na [M+Na]
+ calc'd 438.2733, found 
438.2716. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (S,S)-Ciliatamide C (9 or 20a).  9 was synthesized by the general 
procedure for amide coupling A starting from 18 (70 mg, 0.25 mmol) and 9-
decenoic acid (13, 65 mg, 71 μL, 0.38 mmol) to yield a yellow oil.  Yield: 47% 
(51.4 mg).   [α]D
20 –43 (c 0.10, MeOH); Rf 0.44 (9:1 DCM/MeOH); IR (neat) 3274, 
2926, 2854, 1655, 1527, 1492 cm-1; 1H NMR (CD3CN, 600 MHz, 25 °C): δ 7.20 
(m, 5H), 6.76 (bd, J = 6.6 Hz, 1H, NH), 6.15 (bs, 1H, NH), 5.82 (ddt, J = 17.0, 
10.3, 6.5 Hz, 1H), 5.37 (dd, J = 10.8, 5.2 Hz, 1H), 4.99 (dd,  J = 17.0, 1.5 Hz, 
1H), 4.92 (dt,  J = 10.3, 1.5 Hz, 1H), 4.15 (dt, J = 11.7, 6.6 Hz, 1H), 3.26 (dd, J = 
14.6, 5.2 Hz, 1H), 3.21 (m, 2H), 2.88 (dd, J = 14.6, 10.8 Hz, 1H), 2.80 (s, 3H), 
2.15 (m, 3H), 2.02 (m, 2H), 1.82 (m, 2H), 1.64 (qd, J = 11.7, 4.9 Hz, 1H), 1.33 (m, 
4H), 1.26 (m, 2H), 1.21 (m, 2H), 1.10 (m, 2H); 13C NMR (CD3CN, 150 MHz, 25 
°C): δ 174.8, 171.1, 140.2, 139.3, 129.9, 129.2, 127.2, 114.7, 58.4, 50.9, 42.4, 
34.43, 34.36, 33.9, 32.0, 29.9, 29.8, 29.7, 29.6, 28.4, 25.6, 22.1; LCMS, single 
peak, 3.358 min, ES-API: m/z 877.5 [M2+Na]
+; HRMS (TOF, ES+) C25H37N3O3Na 
[M+Na]+ calc'd 450.2733, found 450.2729. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)octanamide (20b).  Coupling 18 (20 mg, 0.073 mmol) with octanoyl chloride 
(14, 35 mg, 0.22 mmol) using method B afforded the amide 20b as a yellow oil.  
Yield: 47% (13.7 mg).  LCMS, single peak, 3.192 min, ES-API: m/z 825.5 
[M2+Na]
+; HRMS (TOF, ES+) C23H35N3O3Na [M+Na]
+ calc'd 424.2576, found 
424.2565.  
 
 
 
N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)pentanamide (20c).  Coupling 18 (20 mg, 0.073 mmol) with valeroyl chloride 
(26 mg, 26 μL, 0.22 mmol) using method B afforded the amide 20c as a pale 
yellow oil.  Yield: 31% (8.1 mg).  LCMS, single peak, 2.641 min, ES-API: m/z 
741.4 [M2+Na]
+; HRMS (TOF, ES+) C20H29N3O3Na [M+Na]
+ calc'd 382.2107, 
found 382.2092. 
 
 27 
 
 
 
N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)decanamide (20d).  Coupling 18 (20 mg, 0.073 mmol) with decanoyl chloride 
(42 mg, 45 μL, 0.22 mmol) using method B afforded the amide 20d as a yellow 
oil.  Yield: 8% (2.5 mg).  LCMS, single peak, 3.562 min, ES-API: m/z 881.5 
[M2+Na]
+; HRMS (TOF, ES+) C25H39N3O3Na [M+Na]
+ calc'd 452.2889, found 
452.2884. 
 
 
 
N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)nicotinamide (20e).  Coupling 18 (20 mg, 0.073 mmol) with nicotinic acid (13 
mg, 0.110 mmol) using method A afforded the amide 20e as a yellow oil.  Yield: 
46% (16.5 mg).  LCMS, single peak, 1.961 min, ES-API: m/z 381.2 [M+H]+; 
HRMS (TOF, ES+) C21H24N4O3Na [M+Na]
+ calc'd 403.1746, found 403.1752. 
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4-Fluoro-N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (20f).  Coupling 18 (20 mg, 0.073 mmol) with 4-fluorobenzoyl 
chloride (35 mg, 26 μL, 0.22 mmol) using method B afforded the amide 20f as a 
pale yellow oil.  Yield: 29% (8.3 mg).  LCMS, single peak, 2.621 min, ES-API: 
m/z 398.2 [M+H]+; HRMS (TOF, ES+) C22H24FN3O3Na [M+Na]
+ calc'd 420.1699, 
found 420.1692. 
 
 
 
4-(Dimethylamino)-N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-
phenylpropan-2-yl)benzamide (20g).  Coupling 18 (20 mg, 0.073 mmol) with 4-
(dimethylamino)benzoyl chloride (40 mg, 0.22 mmol) using method B afforded 
the amide 20g as a brown oil.  Yield: 30% (11.7 mg).  LCMS, single peak, 2.265 
min, ES-API: m/z 423.3 [M+H]+; HRMS (TOF, ES+) C24H30N4O3Na [M+Na]
+ 
calc'd 445.2216, found 445.2224. 
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4-Ethoxy-N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (20h).  Coupling 18 (20 mg, 0.073 mmol) with 4-ethoxybenzoyl 
chloride (40 mg, 40 μL, 0.22 mmol) using method B afforded the amide 20h as a 
yellow oil.  Yield: 31% (9.5 mg).  LCMS, single peak, 2.747 min, ES-API: m/z 
424.2 [M+H]+; HRMS (TOF, ES+) C24H29N3O4Na [M+Na]
+ calc'd 446.2056, found 
446.2072. 
 
 
 
4-Butoxy-N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (20i).  Coupling 18 (20 mg, 0.073 mmol) with 4-butoxybenzoyl 
chloride (46 mg, 41 μL, 0.22 mmol) using method B afforded the amide 20i as a 
yellow oil.  Yield: 58% (19.0 mg).  LCMS, single peak, 3.117 min, ES-API: m/z 
926.4 [M2+Na]
+; HRMS (TOF, ES+) C26H33N3O4Na [M+Na]
+ calc'd 474.2369, 
found 474.2380. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-2-
naphthamide (20j).  Coupling 18 (20 mg, 0.073 mmol) with 2-naphthoyl chloride 
(42 mg, 0.22 mmol) using method B afforded the amide 20j as a yellow oil.  
Yield: 39% (12.2 mg).  LCMS, single peak, 2.867 min, ES-API: m/z 430.2 [M+H]+; 
HRMS (TOF, ES+) C26H27N3O3Na [M+Na]
+ calc'd 452.1950, found 452.1944. 
 
 
 
4-Methoxy-N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-
2-yl)benzamide (20k).  Coupling 18 (20 mg, 0.073 mmol) with 4-
methoxyphenylacetyl chloride (40 mg, 33 μL, 0.22 mmol) using method B 
afforded the amide 20k as a yellow oil.  Yield: 1% (0.2 mg).  LCMS, single peak, 
2.643 min, ES-API: m/z 424.2 [M+H]+; HRMS (TOF, ES+) C24H29N3O4Na 
[M+Na]+ calc'd 446.2056, found 446.2054. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-3-
phenylpropanamide (20l).  Coupling 18 (20 mg, 0.073 mmol) with 
hydrocinnamoyl chloride (37 mg, 32 μL, 0.22 mmol) using method B afforded the 
amide 20l as a colorless oil.  Yield: 53% (15.6 mg).  1H NMR (DMSO-d6, 600 
MHz, 25 °C): δ 7.84 (t, J = 5.9 Hz, 1H, NH), 7.66 (d, J = 6.3 Hz, 1H, NH), 7.58 (d, 
J = 6.9 Hz, 1H), 7.37 (m, 3H), 7.25 (m, 3H), 7.18 (m, 1H), 7.09 (t, J = 7.2 Hz, 1H), 
7.05 (d, J = 15.2 Hz, 1H), 5.46 (dd, J = 10.3, 6.3 Hz, 1H), 4.37 (dd,  J = 10.3, 6.4 
Hz, 1H), 3.23 (dd, J = 14.4, 5.8 Hz, 1H), 3.16 (m, 2H), 3.05 (s, 3H), 2.94 (q, J = 
12.1 Hz, 1H), 2.87 (s, 2H), 1.86 (m, 1H), 1.78 (m, 1H), 1.73 (m, 1H), 1.63 
(quintet, J = 12.7 Hz, 1H), 1.35 (m, 1H), 1.18 (quintet, J = 11.5 Hz, 1H); 13C NMR 
(DMSO-d6, 150 MHz, 25 °C): δ 173.9, 168.8, 166.3, 142.0, 138.0, 134.9, 129.2, 
128.7, 128.1, 126.2, 118.2, 60.1, 57.1, 51.5, 40.6, 33.9, 31.4, 30.9, 28.8, 27.6; 
LCMS, single peak, 2.805 min, ES-API: m/z 408.2 [M+H]+; HRMS (TOF, ES+) 
C24H29N3O3Na [M+Na]
+ calc'd 430.2107, found 430.2107. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)cinnamamide (20m).  Coupling 18 (20 mg, 0.073 mmol) with cinnamoyl 
chloride (36 mg, 0.22 mmol) using method B afforded the amide 20m as a pale 
yellow oil.  Yield: 18% (5.4 mg).  LCMS, single peak, 2.768 min, ES-API: m/z 
833.3 [M2+Na]
+; HRMS (TOF, ES+) C24H27N3O3Na [M+Na]
+ calc'd 428.1950, 
found 428.1959. 
 
 
 
N–methyl-((S)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)phenoxyacetamide (20n).  Coupling 18 (20 mg, 0.073 mmol) with 2-
phenoxyacetyl chloride (37 mg, 30 μL, 0.22 mmol) using method B afforded the 
amide 20n as a colorless oil.  Yield: 53% (15.8 mg).  1H NMR (DMSO-d6, 600 
MHz, 25 °C): δ 8.05 (bd, J = 7.6 Hz, 1H, NH), 7.60 (m, 1H, NH), 7.33 (m, 1H), 
7.23 (m, 4H), 7.16 (t, J = 7.6 Hz, 2H), 6.87 (t, J = 7.6 Hz, 1H), 6.52 (d, J = 7.6 Hz, 
2H), 5.27 (dd, J = 11.0, 4.6 Hz, 1H), 4.71 (d, J = 15.7 Hz, 1H), 4.52 (d, J = 15.7 
Hz, 1H), 4.16 (m, 1H), 3.26 (dd, J = 14.2, 4.6 Hz, 1H), 3.13 (m, 2H), 2.96 (dd, J = 
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14.2, 11.0 Hz, 1H), 2.86 (s, 3H), 1.91 (m, 1H), 1.78 (m, 1H), 1.72 (m, 2H); 13C 
NMR (DMSO-d6, 150 MHz, 25 °C): δ 169.5, 169.1, 167.9, 157.9, 138.0, 129.1, 
128.9, 128.1, 126.1, 120.5, 114.3, 65.2, 57.3, 49.1, 41.1, 33.7, 29.9, 28.7, 27.6; 
LCMS, single peak, 2.648 min, ES-API: m/z 410.2 [M+H]+; HRMS (TOF, ES+) 
C23H27N3O4Na [M+Na]
+ calc'd 432.1889, found 432.1898. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)pentanamide (21c).  Coupling 19 (21 mg, 0.073 mmol) with valeroyl chloride 
(26 mg, 26 μL, 0.22 mmol) using method B afforded the amide 21c as a colorless 
oil.  Yield: 39% (10.7 mg).  LCMS, single peak, 2.846 min, ES-API: m/z 769.4 
[M2+Na]
+; HRMS (TOF, ES+) C21H31N3O3Na [M+Na]
+ calc'd 396.2263, found 
396.2260. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)decanamide (21d).  Coupling 19 (21 mg, 0.073 mmol) with decanoyl chloride 
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(42 mg, 45 μL, 0.22 mmol) using method B afforded the amide 21d as a colorless 
oil.  Yield: 43% (13.7 mg).  LCMS, single peak, 3.732 min, ES-API: m/z 909.6 
[M2+Na]
+; HRMS (TOF, ES+) C26H41N3O3Na [M+Na]
+ calc'd 466.3046, found 
466.3052. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)nicotinamide (21e).  Coupling 19 (21 mg, 0.073 mmol) with nicotinic acid (13 
mg, 0.110 mmol) using method A afforded the amide 21e as a colorless oil.  
Yield: 33% (12.2 mg).  LCMS, single peak, 2.123 min, ES-API: m/z 395.2 [M+H]+; 
HRMS (TOF, ES+) C22H26N4O3Na [M+Na]
+ calc'd 417.1903, found 417.1894. 
 
 
 
4-Fluoro-N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (21f).  Coupling 19 (21 mg, 0.073 mmol) with 4-fluorobenzoyl 
chloride (35 mg, 26 μL, 0.22 mmol) using method B afforded the amide 21f as a 
yellow oil.  Yield: 32% (9.7 mg).  LCMS, single peak, 2.821 min, ES-API: m/z 
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412.2 [M+H]+; HRMS (TOF, ES+) C23H26FN3O3Na [M+Na]
+ calc'd 434.1856, 
found 434.1853. 
 
 
 
4-(Dimethylamino)-N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-
phenylpropan-2-yl)benzamide (21g).  Coupling 19 (21 mg, 0.073 mmol) with 4-
(dimethylamino)benzoyl chloride (40 mg, 0.22 mmol) using method B afforded 
the amide 21g as a brown oil.  Yield: 33% (13.2 mg).  LCMS, single peak, 2.489 
min, ES-API: m/z 437.3 [M+H]+; HRMS (TOF, ES+) C25H32N4O3Na [M+Na]
+ 
calc'd 459.2372, found 459.2383. 
 
 
 
4-Ethoxy-N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (21h).  Coupling 19 (21 mg, 0.073 mmol) with 4-ethoxybenzoyl 
chloride (40 mg, 40 μL, 0.22 mmol) using method B afforded the amide 21h as a 
yellow oil.  Yield: 36% (11.4 mg).  LCMS, single peak, 2.950 min, ES-API: m/z 
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897.4 [M2+Na]
+; HRMS (TOF, ES+) C25H31N3O4Na [M+Na]
+ calc'd 460.2212, 
found 460.2223. 
 
 
 
4-Butoxy-N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (21i).  Coupling 19 (21 mg, 0.073 mmol) with 4-butoxybenzoyl 
chloride (46 mg, 41 μL, 0.22 mmol) using method B afforded the amide 21i as a 
pale yellow oil.  Yield: 43% (14.4 mg).  LCMS, single peak, 3.322 min, ES-API: 
m/z 953.4 [M2+Na]
+; HRMS (TOF, ES+) C27H35N3O4Na [M+Na]
+ calc'd 488.2525, 
found 488.2541. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-2-
naphthamide (21j).  Coupling 19 (21 mg, 0.073 mmol) with 2-naphthoyl chloride 
(42 mg, 0.22 mmol) using method B afforded the amide 21j as a pale yellow oil.  
Yield: 37% (12.0 mg).  LCMS, single peak, 3.062 min, ES-API: m/z 444.2 [M+H]+; 
HRMS (TOF, ES+) C27H29N3O3Na [M+Na]
+ calc'd 466.2107, found 466.2111  
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4-Methoxy-N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-
2-yl)benzamide (21k).  Coupling 19 (21 mg, 0.073 mmol) with 4-
methoxyphenylacetyl chloride (40 mg, 33 μL, 0.22 mmol) using method B 
afforded the amide 21k as a yellow oil.  Yield: 36% (11.3 mg).  LCMS, single 
peak, 2.830 min, ES-API: m/z 897.4 [M2+Na]
+; HRMS (TOF, ES+) C25H31N3O4Na 
[M+Na]+ calc'd 460.2212, found 460.2209. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-3-
phenylpropanamide (21l).  Coupling 19 (21 mg, 0.073 mmol) with 
hydrocinnamoyl chloride (37 mg, 32 μL, 0.22 mmol) using method B afforded the 
amide 21l as a pale yellow oil.  Yield: 50% (15.4 mg).  1H NMR (DMSO-d6, 600 
MHz, 25 °C): δ 7.86 (m, 1H, NH), 7.60 (d, J = 6.7 Hz, 1H, NH), 7.22 (m, 6H), 7.16 
(m, 2H), 7.11 (d, J = 7.3 Hz, 1H), 7.03 (d, J = 7.3 Hz, 1H), 5.33 (dd, J = 10.4, 5.4 
Hz, 1H), 4.37 (dd, J = 10.9, 7.6 Hz, 1H), 3.18 (dd, J = 14.8, 5.4 Hz, 1H), 3.05 (m, 
2H), 2.86 (dd, J = 14.8, 10.4 Hz, 1H), 2.82 (s, 3H), 2.65 (m, 2H), 2.53 (m, 1H), 
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2.43 (dd, J = 9.2, 6.6 Hz, 1H), 1.87 (m, 1H), 1.75 (m, 2H), 1.64 (m, 1H), 1.37 
(quintet, J = 12.6 Hz, 1H), 1.19 (m, 1H); 13C NMR (DMSO-d6, 150 MHz, 25 °C): δ 
173.9, 172.3, 168.8, 141.3, 138.0, 129.0, 128.8, 128.2, 128.1, 126.1, 125.7, 60.2, 
56.9, 51.5, 40.6, 34.3, 33.8, 30.9, 30.2, 28.8, 27.6; LCMS, single peak, 2.997 
min, ES-API: m/z 444.2 [M+Na]+; HRMS (TOF, ES+) C25H31N3O3Na [M+Na]
+ 
calc'd 444.2263, found 444.2250. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)cinnamamide (21m).  Coupling 19 (21 mg, 0.073 mmol) with cinnamoyl 
chloride (36 mg, 0.22 mmol) using method B afforded the amide 21m as a pale 
yellow oil.  Yield: 41% (12.6 mg).  LCMS, single peak, 2.947 min, ES-API: m/z 
861.4 [M2+Na]
+; HRMS (TOF, ES+) C25H29N3O3Na [M+Na]
+ calc'd 442.2107, 
found 442.2114. 
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N-methyl-((S)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)phenoxyacetamide (21n).  Coupling 19 (21 mg, 0.073 mmol) with 2-
phenoxyacetyl chloride (37 mg, 30 μL, 0.22 mmol) using method B afforded the 
amide 21n as a colorless oil.  Yield: 43% (13.1 mg).  1H NMR (DMSO-d6, 600 
MHz, 25 °C): δ 7.84 (t, J = 6.0 Hz, 1H, NH), 7.74 (d, J = 7.2 Hz, 1H, NH), 7.33 
(m, 1H), 7.24 (m, 4H), 7.17 (t, J = 7.7 Hz, 2H), 6.88 (t, J = 7.7 Hz, 1H), 6.57 (d, J 
= 7.7 Hz, 2H), 5.29 (dd, J = 10.7, 5.0 Hz, 1H), 4.75 (d, J = 15.2 Hz, 1H), 4.56 (d, 
J = 15.2 Hz, 1H), 4.40 (dd, J = 9.7, 7.2 Hz, 1H), 3.22 (dd, J = 14.2, 5.0 Hz, 1H), 
3.17 (m, 1H), 3.06 (m, 1H), 2.99 (dd, J = 14.2, 10.7 Hz, 1H), 2.89 (s, 3H), 1.88 
(m, 1H), 1.82 (m, 1H), 1.75 (m, 1H), 1.64 (m, 1H), 1.41 (quintet, J = 12.4 Hz, 1H), 
1.20 (quintet, J = 12.4 Hz, 1H); 13C NMR (DMSO-d6, 150 MHz, 25 °C): δ 173.9, 
168.4, 168.1, 157.9, 137.9, 129.2, 128.8, 128.2, 126.2, 120.5, 114.3, 65.2, 57.0, 
51.5, 40.6, 33.6, 30.9, 29.9, 28.8, 27.6; LCMS, single peak, 2.834 min, ES-API: 
m/z 424.2 [M+H]+; HRMS (TOF, ES+) C24H29N3O4Na [M+Na]
+ calc'd 446.2056, 
found 446.2041. 
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tert-butyl methyl((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)carbamate (40).  40 was synthesized by the procedure used for 16 starting 
from Boc-N-methyl-L-phenylalanine (15, 668 mg, 2.39 mmol) and (R)-3-
aminoazepan-2-one (255 mg, 1.99 mmol) to yield a pale yellow oil.  LCMS, single 
peak, 3.019 min, ES-API: m/z 390.3 [M+H]+. 
 
 
 
N-(R)-azepan-2-one-3-yl-(S)-2-methylamino-3-phenylpropanamide (41).  41 
was synthesized by the procedure used for 18 starting from 40 (776 mg, 1.99 
mmol) to yield a pale yellow oil.  2-step yield: 85% (491 mg).  [α]D
20 +27 (c 0.25, 
MeOH); Rf 0.32 (9:1 DCM/MeOH); IR (neat) 3318, 2931, 2855, 1653, 1508, 
1478, 1435 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.26 (t, J = 7.5 Hz, 2H), 
7.20 (m, 3H), 4.46 (dd, J = 11.5, 1.4 Hz, 1H), 3.32 (m, 1H), 3.25 (dd, J = 14.8, 
11.5 Hz, 1H), 3.18 (bdd, J = 14.2, 4.4 Hz, 1H),  2.88 (m, 2H), 2.29 (s, 3H), 1.91 
(dt, J = 14.0, 3.3 Hz, 1H), 1.80 (dd, J = 14.2, 4.1 Hz, 1H), 1.72 (qt, J = 13.2, 3.5 
Hz, 1H), 1.58 (d, J = 13.7 Hz, 1H), 1.32 (m, 2H); 13C NMR (CD3OD, 150 MHz, 25 
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°C): δ 176.8, 174.6, 138.8, 130.3, 129.5, 127.7, 66.9, 53.0, 42.4, 40.5, 34.7, 32.2, 
29.9, 29.0; LCMS, single peak, 1.886 min, ES-API: m/z 290.2 [M+H]+; HRMS 
(TOF, ES+) C16H23N3O2Na [M+Na]
+ calc'd 312.1688, found 312.1691. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (R,S)-Ciliatamide A, (22a or 24).  24 was synthesized by the general 
procedure for amide coupling A starting from 41 (33 mg, 0.12 mmol) and 9-
decenoic acid (13, 29 mg, 32 μL, 0.17 mmol) to yield a pale brown oil.  Yield: 
19% (9.5 mg).  [α]D
20 –48 (c 0.05, MeOH); Rf 0.46 (9:1 DCM/MeOH); IR (neat) 
3286, 2926, 2854, 1655, 1479, 1289 cm-1; 1H NMR (DMSO-d6, 600 MHz, 25 °C): 
δ 7.83 (m, 1H, NH), 7.56 (bd, J = 6.2 Hz, 1H, NH), 7.22 (m, 4H), 7.14 (t, J = 6.8 
Hz, 1 H), 5.78 (ddt, J = 17.2, 10.3, 6.9 Hz, 1H), 5.36 (dd, J = 10.5, 5.5 Hz, 1H), 
4.99 (dd,  J = 17.2, 1.4 Hz, 1H), 4.93 (dt,  J = 10.3, 1.4 Hz, 1H), 4.34 (dd,  J = 
9.9, 4.3 Hz, 1H), 3.16 (dd, J = 14.1, 5.5 Hz, 1H), 3.04 (bdd, J = 13.8, 4.9 Hz, 2H), 
2.88 (dd, J = 14.1, 10.5 Hz, 1H), 2.83 (s, 3H), 2.12 (t, J = 7.1 Hz, 2H), 1.99 (q, J = 
6.9 Hz, 2H), 1.86 (m, 1H), 1.77 (m, 1H), 1.74 (m, 1H), 1.71 (m, 1H), 1.61 (m, 1H), 
1.38 (qd, J = 13.8, 4.9 Hz, 1H), 1.29 (m, 4H), 1.17 (m, 4H), 1.07 (m, 2H); 13C 
NMR (DMSO-d6, 150 MHz, 25 °C): δ 173.9, 172.9, 168.9, 138.8, 137.9, 128.8, 
128.0, 126.1, 114.6, 56.5, 51.5, 40.6, 33.8, 33.2, 32.6, 31.2, 30.9, 28.8, 28.6, 
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28.4, 28.2, 27.6, 24.4; LCMS, single peak, 3.532 min, ES-API: m/z 442.3 [M+H]+; 
HRMS (TOF, ES+) C26H39N3O3Na [M+Na]
+ calc'd 464.2889, found 464.2905. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)octanamide, (R,S)-Ciliatamide B (22b or 27).  27 was synthesized according 
to the general procedure for amide coupling B starting from amine 41 (33 mg, 
0.12 mmol) and octanoyl chloride (56 mg, 59 μL, 0.35 mmol) to yield a pale 
yellow oil.  Yield: 24% (11.3 mg).  [α]D
20 –50 (c 0.10, MeOH); Rf 0.44 (9:1 
DCM/MeOH); IR (neat) 3286, 2928, 2855, 1656, 1479, 1288 cm-1; 1H NMR 
(DMSO-d6, 600 MHz, 25 °C): δ  7.87 (m, 1H, NH), 7.60 (bd, J = 6.5 Hz, 1H, NH), 
7.22 (m, 5H), 7.14 (t, J = 6.8 Hz, 1H), 5.37 (dd, J = 10.5, 5.6 Hz, 1H), 4.34 (dd,  J 
= 10.0, 6.4 Hz, 1H), 3.16 (m, 2H), 3.04 (m, 1H), 2.88 (dd, J = 14.5, 10.5 Hz, 1H), 
2.83 (s, 3H), 2.12 (dt, J = 7.4, 2.3 Hz, 2H), 1.86 (m, 1H), 1.74 (m, 2H), 1.62 (m, 
1H), 1.38 (m, 1H), 1.28 (quintet, J = 7.4 Hz, 2H), 1.22 (m, 3H), 1.15 (m, 4H), 1.06 
(m, 1H), 1.02 (m, 1H), 0.84 (t, J = 7.2, 3H); 13C NMR (DMSO-d6, 150 MHz, 25 
°C): δ 174.0, 172.9, 168.9, 137.9, 128.8, 128.0, 126.1, 60.5, 56.5, 51.5, 33.8, 
32.6, 31.2, 31.1, 30.9, 28.8, 28.5, 28.4, 27.6, 24.4, 22.0, 13.9; LCMS, single 
peak, 3.384 min, ES-API: m/z 416.3 [M+H]+; HRMS (TOF, ES+) C24H37N3O3Na 
[M+Na]+ calc'd 438.2733, found 438.2731. 
 43 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)pentanamide (22c).  Coupling 41 (21 mg, 0.073 mmol) with valeroyl chloride 
(26 mg, 26 μL, 0.22 mmol) using method B afforded the amide 22c as a yellow 
oil.  Yield: 13% (3.3 mg).  LCMS, single peak, 2.842 min, ES-API: m/z 374.2 
[M+H]+; HRMS (TOF, ES+) C21H31N3O3Na [M+Na]
+ calc'd 396.2263, found 
396.2261.  
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)decanamide (22d).  Coupling 41 (21 mg, 0.073 mmol) with decanoyl chloride 
(42 mg, 45 μL, 0.22 mmol) using method B afforded the amide 22d as a pale 
yellow oil.  Yield: 56% (17.1 mg).  LCMS, single peak, 3.731 min, ES-API: m/z 
444.3 [M+H]+; HRMS (TOF, ES+) C26H41N3O3Na [M+Na]
+ calc'd 466.3046, found 
466.3047. 
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N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)nicotinamide (22e).  Coupling 41 (21 mg, 0.073 mmol) with nicotinic acid (13 
mg, 0.11 mmol) using method A afforded the amide 22e as a pale yellow oil.  
Yield: 23% (8.1 mg).  LCMS, single peak, 2.163 min, ES-API: m/z 395.2 [M+H]+; 
HRMS (TOF, ES+) C22H26N4O3Na [M+Na]
+ calc'd 417.1903, found 417.1902. 
 
 
 
4-Fluoro-N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (22f).  Coupling 41 (21 mg, 0.073 mmol) with 4-fluorobenzoyl 
chloride (35 mg, 26 μL, 0.22 mmol) using method B afforded the amide 22f as a 
pale yellow oil.  Yield: 29% (8.6 mg).  LCMS, single peak, 2.851 min, ES-API: 
m/z 412.2 [M+H]+; HRMS (TOF, ES+) C23H26FN3O3Na [M+Na]
+ calc'd 434.1856, 
found 434.1852. 
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4-(Dimethylamino)-N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-
phenylpropan-2-yl)benzamide (22g).  Coupling 41 (21 mg, 0.073 mmol) with 4-
(dimethylamino)benzoyl chloride (40 mg, 0.22 mmol) using method B afforded 
the amide 22g as a brown oil.  Yield: 35% (14.0 mg).  LCMS, single peak, 2.492 
min, ES-API: m/z 437.3 [M+H]+; HRMS (TOF, ES+) C25H32N4O3Na [M+Na]
+ 
calc'd 459.2372, found 459.2368. 
 
 
 
4-Ethoxy-N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (22h).  Coupling 41 (21 mg, 0.073 mmol) with 4-ethoxybenzoyl 
chloride (40 mg, 40 μL, 0.22 mmol) using method B afforded the amide 22h as a 
pale yellow oil.  Yield: 39% (12.5 mg).  LCMS, single peak, 2.970 min, ES-API: 
m/z 438.3 [M+H]+; HRMS (TOF, ES+) C25H31N3O4Na [M+Na]
+ calc'd 460.2212, 
found 460.2228. 
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4-Butoxy-N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)benzamide (22i).  Coupling 41 (21 mg, 0.073 mmol) with 4-butoxybenzoyl 
chloride (46 mg, 41 μL, 0.22 mmol) using method B afforded the amide 22i as a 
yellow oil.  Yield: 25% (8.0 mg).  LCMS, single peak, 3.325 min, ES-API: m/z 
466.3 [M+H]+; HRMS (TOF, ES+) C27H35N3O4Na [M+Na]
+ calc'd 488.2525, found 
488.2542. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-2-
naphthamide (22j).  Coupling 41 (21 mg, 0.073 mmol) with 2-naphthoyl chloride 
(42 mg, 0.22 mmol) using method B afforded the amide 22j as a yellow oil.  
Yield: 28% (8.9 mg).  LCMS, single peak, 3.089 min, ES-API: m/z 444.2 [M+H]+; 
HRMS (TOF, ES+) C27H29N3O3Na [M+Na]
+ calc'd 466.2107, found 466.2120. 
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4-Methoxy-N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-
2-yl)benzamide (22k).  Coupling 41 (21 mg, 0.073 mmol) with 4-
methoxyphenylacetyl chloride (40 mg, 33 μL, 0.22 mmol) using method B 
afforded the amide 22k as a pale yellow oil.  Yield: 20% (6.1 mg).  LCMS, single 
peak, 2.840 min, ES-API: m/z 438.3 [M+H]+; HRMS (TOF, ES+) C25H31N3O4Na 
[M+Na]+ calc'd 460.2212, found 460.2213. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)-3-
phenylpropanamide (22l).  Coupling 41 (21 mg, 0.073 mmol) with 
hydrocinnamoyl chloride (37 mg, 32 μL, 0.22 mmol) using method B afforded the 
amide 22l as a colorless oil.  Yield: 47% (13.6 mg).  1H NMR (DMSO-d6, 600 
MHz, 25 °C): δ 7.85 (t, J = 6.1 Hz, 1H, NH), 7.61 (d, J = 6.2 Hz, 1H, NH), 7.23 
(m, 6H), 7.14 (m, 3H), 7.03 (d, J = 6.9 Hz, 1H), 4.82 (dd, J = 10.5, 4.6 Hz, 1H), 
4.35 (dd, J = 10.0, 6.4 Hz, 1H), 3.17 (m, 2H), 3.09 (dd, J = 14.1, 4.6 Hz, 1H), 
2.90 (dd, J = 14.1, 10.5 Hz, 1H), 2.85 (s, 3H), 2.64 (m, 2H), 2.53 (dd, J = 15.6, 
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6.5 Hz, 1H), 2.43 (dd, J = 9.2, 6.5 Hz, 1H), 1.86 (m, 1H), 1.73 (m, 2H), 1.62 (m, 
1H), 1.32 (quintet, J = 12.6 Hz, 1H), 1.18 (m, 1H); 13C NMR (DMSO-d6, 150 MHz, 
25 °C): δ 173.9, 172.2, 168.8, 141.2, 137.9, 129.2, 128.8, 128.2, 128.1, 126.1, 
125.8, 60.2, 56.8, 51.5, 40.6, 34.4, 33.9, 30.9, 30.3, 28.8, 27.6; LCMS, single 
peak, 3.003 min, ES-API: m/z 422.3 [M+H]+; HRMS (TOF, ES+) C25H31N3O3Na 
[M+Na]+ calc'd 444.2263, found 444.2247. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)cinnamamide (22m).  Coupling 41 (21 mg, 0.073 mmol) with cinnamoyl 
chloride (36 mg, 0.22 mmol) using method B afforded the amide 22m as a pale 
yellow oil.  Yield: 43% (12.4 mg).  LCMS, single peak, 2.959 min, ES-API: m/z 
421.3 [M+H]+; HRMS (TOF, ES+) C25H29N3O3Na [M+Na]
+ calc'd 442.2107, found 
442.2120. 
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N-methyl-((R)-azepan-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)phenoxyacetamide (22n).  Coupling 41 (21 mg, 0.073 mmol) with 2-
phenoxyacetyl chloride (37 mg, 30 μL, 0.22 mmol) using method B afforded the 
amide 22n as a yellow oil.  Yield: 57% (16.6 mg).  1H NMR (DMSO-d6, 600 MHz, 
25 °C): δ 7.84 (m, 1H, NH), 7.73 (bd, J = 6.6 Hz, 1H, NH), 7.33 (m, 1H), 7.25 (m, 
4H), 7.17 (t, J = 7.9 Hz, 2H), 6.88 (t, J = 7.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 
6.49 (d, J = 7.9 Hz, 1H), 5.33 (dd, J = 10.6, 5.4 Hz, 1H), 4.74 (d, J = 15.6 Hz, 
1H), 4.56 (d, J = 15.6 Hz, 1H), 4.39 (dd, J = 10.2, 6.8 Hz, 1H), 3.19 (dd, J = 13.9, 
5.4 Hz, 1H), 3.15 (m, 1H), 3.06 (m, 1H), 2.97 (dd, J = 13.9, 10.6 Hz, 1H), 2.93 (s, 
3H), 1.90 (m, 1H), 1.74 (m, 2H), 1.63 (m, 1H), 1.39 (quintet, J = 12.5 Hz, 1H), 
1.20 (m, 1H); 13C NMR (DMSO-d6, 150 MHz, 25 °C): δ 173.9, 168.6, 168.0, 
157.9, 137.7, 129.2, 128.9, 128.1, 126.2, 120.5, 114.3, 65.2, 56.8, 51.5, 40.6, 
33.7, 30.8, 29.9, 28.8, 27.6; LCMS, single peak, 2.858 min, ES-API: m/z 424.2 
[M+H]+; HRMS (TOF, ES+) C24H29N3O4Na [M+Na]
+ calc'd 446.2056, found 
446.2073. 
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tert-butyl methyl((S)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)carbamate (42).  42 was synthesized using the general procedure for amide 
coupling C starting from Boc-N-methyl-D-phenylalanine (30, 409 mg, 1.46 mmol) 
and (S)-3-aminoazepan-2-one (10, 125 mg, 0.98 mmol) to yield a yellow oil.  
LCMS, single peak, 3.000 min, ES-API: m/z 390.2 [M+H]+. 
 
 
 
tert-butyl methyl((R)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)carbamate (43).  43 was synthesized using the general procedure for amide 
coupling C starting from Boc-N-methyl-D-phenylalanine (30, 409 mg, 1.46 mmol) 
and (R)-3-aminoazepan-2-one (125 mg, 0.98 mmol) to yield a pale yellow oil.  
LCMS, single peak, 2.982 min, ES-API: m/z 390.3 [M+H]+. 
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N-(S)-azepan-2-one-3-yl-(R)-2-methylamino-3-phenylpropanamide (44).  44 
was synthesized by the procedure used for 18 starting from 42 (380 mg, 0.98 
mmol) to yield a colorless oil.  2-step yield: 38% (107 mg).  [α]D
20 -25 (c 0.10, 
MeOH); Rf 0.32 (9:1 DCM/MeOH); IR (neat) 3318, 2931, 2855, 1653, 1508, 
1478, 1435 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.26 (t, J = 7.4 Hz, 2H), 
7.20 (m, 3H), 4.46 (dd, J = 11.3, 1.8 Hz, 1H), 3.31 (m, 1H), 3.25 (dd, J = 14.6, 
11.5 Hz, 1H), 3.18 (bdd, J = 13.5, 3.8 Hz, 1H),  2.88 (m, 2H), 2.29 (s, 3H), 1.91 
(dt, J = 14.8, 4.1 Hz, 1H), 1.80 (dd, J = 14.3, 4.5 Hz, 1H), 1.72 (qt, J = 13.5, 3.8 
Hz, 1H), 1.58 (d, J = 13.8 Hz, 1H), 1.32 (m, 2H); 13C NMR (CD3OD, 150 MHz, 25 
°C): δ 176.8, 174.7, 138.8, 130.3, 129.5, 127.7, 66.9, 53.0, 42.4, 40.5, 34.7, 32.2, 
29.9, 29.0; LCMS, single peak, 1.878 min, ES-API: m/z 290.2 [M+H]+; HRMS 
(TOF, ES+) C16H23N3O2Na [M+Na]
+ calc'd 312.1688, found 312.1691. 
 
 
 
N-(R)-azepan-2-one-3-yl-(R)-2-methylamino-3-phenylpropanamide (45).  45 
was synthesized by the procedure used for 18 starting from 43 (380 mg, 0.98 
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mmol) to yield a pale yellow oil.  2-step yield: 86% (242 mg).  [α]D
20 +6 (c 0.10, 
MeOH); Rf 0.32 (9:1 DCM/MeOH); IR (neat) 3318, 2931, 2855, 1653, 1508, 
1478, 1435 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.27 (t, J = 7.4 Hz, 2H), 
7.21 (m, 3H), 4.46 (dd, J = 11.3, 1.6 Hz, 1H), 3.26 (m, 2H), 3.20 (dd, J = 15.1, 5.0 
Hz, 1H), 3.01 (dd, J = 13.7, 5.5 Hz, 1H), 2.80 (dd, J = 13.7, 7.7 Hz, 2H), 2.28 (s, 
3H), 1.97 (dt, J = 14.4, 3.5 Hz, 1H), 1.83 (m, 3H), 1.45 (qd, J = 12.3, 2.9 Hz, 1H), 
1.35 (m, 1H); 13C NMR (CD3OD, 150 MHz, 25 °C): δ 176.8, 174.9, 138.7, 130.3, 
129.5, 127.8, 67.0, 53.0, 42.5, 40.3, 35.1, 32.7, 29.9, 29.0; LCMS, single peak, 
1.664 min, ES-API: m/z 290.2 [M+H]+; HRMS (TOF, ES+) C16H23N3O2Na 
[M+Na]+ calc'd 312.1688, found 312.1688. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (S,R)-Ciliatamide A (23).  23 was synthesized by the general 
procedure for amide coupling A starting from 44 (50 mg, 0.17 mmol) and 9-
decenoic acid (13, 43 mg, 47 μL, 0.25 mmol) to yield a colorless oil.  Yield: 16% 
(12.0 mg).  [α]D
20 +70 (c 0.05, MeOH); Rf 0.46 (9:1 DCM/MeOH); IR (neat) 3286, 
2926, 2854, 1655, 1479, 1289 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.23 
(m, 4H), 7.17 (t, J = 7.0 Hz, 1 H), 5.80 (ddt,  J = 17.0, 10.2, 6.9 Hz, 1H), 5.42 (dd, 
J = 10.3, 5.6 Hz, 1H), 4.97 (dd,  J = 17.0, 1.7 Hz, 1H), 4.91 (dt,  J = 10.2, 1.7 Hz, 
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1H), 4.52 (dd,  J = 11.3, 1.6 Hz, 1H), 3.33 (dd, J = 14.5, 5.6 Hz, 1H), 3.21 (bdd, J 
= 12.9, 2.4 Hz, 2H), 2.97 (dd, J = 14.5, 10.3 Hz, 1H), 2.91 (s, 3H), 2.25 (t, J = 7.5 
Hz, 2H), 2.03 (q, J = 6.9 Hz, 2H), 1.99 (m, 1H), 1.89 (m, 1H), 1.83 (m, 1H), 1.77 
(m, 1H), 1.58 (m, 1H), 1.49 (qd, J = 12.9, 2.4 Hz, 1H), 1.37 (m, 4H), 1.28 (m, 2H), 
1.24 (m, 2H), 1.16 (m, 2H); 13C NMR (CD3OD, 150 MHz, 25 °C): δ 176.9, 176.8, 
171.3, 140.1, 138.8, 130.1, 129.4, 127.6, 114.7, 59.5, 53.4, 42.5, 35.0, 34.9, 
34.4, 32.8, 32.2, 30.3, 30.2, 30.1, 30.0, 29.9, 29.1, 26.0; LCMS, single peak, 
3.508 min, ES-API: m/z 442.3 [M+H]+; HRMS (TOF, ES+) C26H39N3O3Na 
[M+Na]+ calc'd 464.2889, found 464.2903. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (R,R)-Ciliatamide A (25).  25 was synthesized by the general 
procedure for amide coupling A starting from 45 (50 mg, 0.17 mmol) and 9-
decenoic acid (13, 43 mg, 47 μL, 0.25 mmol) to yield a colorless oil.  Yield: 20% 
(15.6 mg).  [α]D
20 +42 (c 0.05, MeOH); Rf 0.46 (9:1 DCM/MeOH); IR (neat) 3286, 
2926, 2854, 1655, 1479, 1289 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.23 
(m, 4H), 7.17 (t, J = 7.1 Hz, 1 H), 5.80 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.37 (dd, 
J = 11.0, 5.5 Hz, 1H), 4.97 (dd,  J = 17.0, 1.2 Hz, 1H), 4.91 (dt,  J = 10.2, 1.2 Hz, 
1H), 4.53 (dd,  J = 11.2, 1.5 Hz, 1H), 3.27 (dd, J = 14.6, 5.5 Hz, 1H), 3.21 (bdd, J 
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= 14.1, 2.7 Hz, 2H), 3.04 (dd, J = 14.6, 11.0 Hz, 1H), 2.90 (s, 3H), 2.23 (t, J = 7.4 
Hz, 2H), 2.03 (q, J = 6.7 Hz, 2H), 1.93 (m, 1H), 1.99 (m, 1H), 1.83 (m, 1H), 1.78 
(m, 1H), 1.60 (m, 1H), 1.51 (qd, J = 14.1, 2.7 Hz, 1H), 1.38 (m, 2H), 1.34 (m, 2H), 
1.28 (m, 2H), 1.24 (m, 2H), 1.16 (m, 2H); 13C NMR (CD3OD, 150 MHz, 25 °C): δ 
176.9, 176.7, 171.6, 140.1, 138.8, 130.1, 129.5, 127.7, 114.7, 59.7, 53.5, 42.5, 
35.1, 34.9, 34.4, 33.1, 32.2, 30.4, 30.3, 30.2, 30.0, 29.9, 29.1, 26.1; LCMS, single 
peak, 3.508 min, ES-API: m/z 905.5 [M2+Na]
+; HRMS (TOF, ES+) C26H39N3O3Na 
[M+Na]+ calc'd 464.2889, found 464.2888. 
 
 
 
N-methyl-((S)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)octanamide, (S,R)-Ciliatamide B (26).  26 was synthesized according to the 
general procedure for amide coupling B starting from amine 44 (80 mg, 0.28 
mmol) and octanoyl chloride (14, 135 mg, 142 μL, 0.83 mmol) to yield a pale 
yellow oil.  Yield: 33% (37.5 mg).  [α]D
20 +68 (c 0.10, MeOH); Rf 0.44 (9:1 
DCM/MeOH); IR (neat) 3286, 2928, 2855, 1656, 1479, 1288 cm-1; 1H NMR 
(CD3CN, 600 MHz, 25 °C): δ 7.20 (m, 5H), 7.09 (bd, J = 4.1 Hz, 1H, NH), 6.41 
(bs, 1H, NH), 5.37 (dd, J = 10.3, 5.4 Hz, 1H), 4.36 (ddd, J = 11.1, 5.7, 1.2 Hz, 
1H), 3.24 (dd, J = 14.6, 5.7 Hz, 1H), 3.15 (m, 2H), 2.89 (dd, J = 14.6, 10.3 Hz, 
1H), 2.83 (s, 3H), 2.17 (m, 2H), 1.95 (m, 1H), 1.89 (m, 2H), 1.77 (m, 1H), 1.70 
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(m, 1H), 1.38 (quintet, J = 7.5 Hz, 2H), 1.33 (m, 1H), 1.26 (m, 2H), 1.21 (m, 4H), 
1.14 (m, 2H), 0.87 (t, J = 7.2, 3H); 13C NMR (CD3CN, 150 MHz, 25 °C): δ 175.6, 
174.8, 170.1, 139.3, 129.9, 129.2, 127.2, 58.3, 53.0, 42.1, 34.3, 34.0, 32.5, 32.2, 
32.0, 29.83, 29.79, 29.7, 28.8, 25.7, 23.3, 14.4; LCMS, single peak, 3.353 min, 
ES-API: m/z 416.3 [M+H]+; HRMS (TOF, ES+) C24H37N3O3Na [M+Na]
+ calc'd 
438.2733, found 438.2724. 
 
 
 
N-methyl-((R)-azepan-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)octanamide, (R,R)-Ciliatamide B (28).  28 was synthesized according to the 
general procedure for amide coupling B starting from amine 45 (82 mg, 0.28 
mmol) and octanoyl chloride (14, 138 mg, 146 μL, 0.85 mmol) to yield a colorless 
oil.  Yield: 44% (50.9 mg).  [α]D
20 +49 (c 0.10, MeOH); Rf 0.44 (9:1 DCM/MeOH); 
IR (neat) 3286, 2928, 2855, 1656, 1479, 1288 cm-1; 1H NMR (CD3CN, 600 MHz, 
25 °C): δ 7.22 (m, 5H), 7.09 (bd, J = 4.8 Hz, 1 H, NH), 6.41 (bs, 1H, NH), 5.37 
(dd, J = 10.4, 5.6 Hz, 1H), 4.39 (ddd,  J = 11.3, 5.9, 1.5 Hz, 1H), 3.32 (dd, J = 
14.7, 5.6 Hz, 1H), 3.15 (m, 2H), 2.91 (dd, J = 14.7, 10.4 Hz, 1H), 2.82 (s, 3H), 
2.18 (m, 2H), 1.97 (m, 1H), 1.89 (m, 2H), 1.77 (m, 1H), 1.71 (m, 1H), 1.38 
(quintet, J = 7.5 Hz, 2H), 1.31 (m, 1H), 1.27 (m, 2H), 1.21 (m, 4H), 1.14 (m, 2H), 
0.87 (t, J = 7.0, 3H); 13C NMR (CD3CN, 150 MHz, 25 °C): δ 175.4, 174.8, 169.9, 
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139.3, 129.9, 129.2, 127.2, 58.2, 53.0, 42.1, 34.2, 33.9, 32.45, 32.43, 31.8, 
29.81, 29.79, 29.7, 28.8, 25.8, 23.3, 14.4; LCMS, single peak, 3.351 min, ES-
API: m/z 853.5 [M2+Na]
+; HRMS (TOF, ES+) C24H37N3O3Na [M+Na]
+ calc'd 
438.2733, found 438.2719. 
 
 
 
tert-butyl methyl((S)-piperid-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)carbamate (31).  31 was synthesized by amide coupling procedure D starting 
from Boc-N-methyl-D-phenylalanine (30, 30 mg, 0.11 mmol) and (S)-3-
aminopiperid-2-one (11, 16 mg, 0.11 mmol) to yield a pale yellow oil.  LCMS, 
single peak, 2.747 min, ES-API: m/z 376.3 [M+H]+. 
 
 
 
tert-butyl methyl((R)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-
yl)carbamate (32).  32 was synthesized using amide coupling procedure D 
starting from Boc-N-methyl-L-phenylalanine (15, 419 mg, 1.50 mmol) and (R)-3-
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aminopiperid-2-one (29, 226 mg, 1.50 mmol) to yield a pale yellow oil.  LCMS, 
single peak, 2.742 min, ES-API: m/z 376.3 [M+H]+. 
 
 
 
tert-butyl methyl((R)-piperid-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-
yl)carbamate (33).  33 was synthesized using amide coupling procedure D 
starting from 30 (336 mg, 1.20 mmol) and 29 (181 mg, 1.20 mmol) to yield a pale 
yellow oil.  LCMS, single peak, 2.740 min, ES-API: m/z 376.3 [M+H]+. 
 
 
 
N-(S)-piperid-2-one-3-yl-(R)-2-methylamino-3-phenylpropanamide (34).  A 
solution of 31 (40 mg, 0.11 mmol) in anhydrous CH2Cl2 (30 mM) was cooled in 
an ice bath before slowly adding a solution of TFA for a final concentration of 5% 
TFA (v/v).  The solution was stirred for 7 hours while cooling in an ice bath.  The 
mixture was co-evaporated with MeOH (3 × 10 mL) before loading onto a Varian 
Bond Elut 10 g SCX cartridge in minimal CH2Cl2.  The cartridge was washed with 
25 mL each of CH2Cl2 then MeOH and was then eluted with 2 M NH3 in MeOH, 
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and these elution fractions were concentrated by rotary evaporation to a 
colorless oil.  2-step yield: 73% (21.4 mg).  [α]D
20 -36 (c 0.25, MeOH); Rf 0.17 (9:1 
DCM/MeOH); IR (neat) 3281, 3225, 2921, 2866, 1644, 1552, 1492, 1325 cm-1; 
1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.27 (t, J = 7.7 Hz, 2H), 7.21 (m, 3H), 4.30 
(dd, J = 10.6, 5.9 Hz, 1H), 3.37 (t, J = 7.4 Hz, 1H), 3.21 (m, 2H), 2.93 (m, 2H), 
2.40 (s, 3H), 1.82 (m, 1H), 1.74 (m, 2H), 1.40 (m, 1H); 13C NMR (CD3OD, 150 
MHz, 25 °C): δ 174.1, 172.4, 138.1, 130.5, 129.6, 127.9, 66.5, 50.4, 42.7, 40.0, 
34.2, 28.6, 21.9; LCMS, single peak, 1.732 min, ES-API: m/z 276.2 [M+H]+; 
HRMS (TOF, ES+) C15H21N3O2Na [M+Na]
+ calc'd 298.1531, found 298.1534. 
 
 
 
N-(R)-piperid-2-one-3-yl-(S)-2-methylamino-3-phenylpropanamide (35).  35 
was synthesized by the procedure used for 34 starting from 32 (563 mg, 1.50 
mmol) to yield a colorless oil.  2-step yield: 43% (177 mg).  [α]D
20 +51 (c 0.25, 
MeOH); Rf 0.17 (9:1 DCM/MeOH); IR (neat) 3281, 3225, 2921, 2866, 1644, 
1552, 1492, 1325 cm-1; 1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.26 (t, J = 7.5 Hz, 
2H), 7.21 (m, 3H), 4.28 (dd, J = 10.5, 6.0 Hz, 1H), 3.25 (t, J = 7.4 Hz, 1H), 3.21 
(dd, J = 9.4, 5.8 Hz, 2H), 2.88 (d, J = 7.4 Hz, 2H), 2.33 (s, 3H), 1.83 (m, 1H), 1.74 
(m, 2H), 1.41 (m, 1H); 13C NMR (CD3OD, 150 MHz, 25 °C): δ 175.5, 172.5, 
138.8, 130.4, 129.5, 127.7, 67.0, 50.4, 42.7, 40.5, 34.6, 28.6, 21.9; LCMS, single 
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peak, 1.733 min, ES-API: m/z 276.2 [M+H]+; HRMS (TOF, ES+) C15H21N3O2Na 
[M+Na]+ calc'd 298.1531, found 298.1528. 
 
 
 
N-(R)-piperid-2-one-3-yl-(R)-2-methylamino-3-phenylpropanamide (36).  36 
was synthesized starting from 33 (451 mg, 1.20 mmol) in anhydrous CH2Cl2 (30 
mM) cooled in an ice bath followed by a slow addition of a solution of TFA for a 
final concentration of 7% TFA (v/v) with continued stirring in an ice bath for 7 h.  
Compound 36 was purified by the same procedure used for 34 to yield a 
colorless oil.  2-step yield: 67% (222 mg).  [α]D
20 -1 (c 0.25, MeOH); Rf 0.16 (9:1 
DCM/MeOH); IR (neat) 3281, 3225, 2921, 2866, 1644, 1552, 1492, 1325 cm-1; 
1H NMR (CD3OD, 600 MHz, 25 °C): δ 7.27 (t, J = 7.4 Hz, 2H), 7.22 (m, 3H), 4.14 
(dd, J = 11.1, 6.2 Hz, 1H), 3.32 (m, 1H), 3.26 (m, 2H), 3.00 (dd, J = 13.6, 6.2 Hz, 
2H), 2.85 (dd, J = 13.6, 7.0 Hz, 2H), 2.32 (s, 3H), 1.99 (m, 1H), 1.88 (m, 1H), 
1.81 (m, 1H), 1.72 (qd, J = 11.8, 3.5 Hz, 1H); 13C NMR (CD3OD, 150 MHz, 25 
°C): δ 175.2, 172.5, 138.5, 130.5, 129.5, 127.8, 66.6, 51.0, 42.7, 40.1, 34.7, 28.6, 
22.3; LCMS, single peak, 1.706 min, ES-API: m/z 276.2 [M+H]+; HRMS (TOF, 
ES+) C15H21N3O2Na [M+Na]
+ calc'd 298.1531, found 298.1538. 
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N-methyl-((S)-piperid-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (S,R)-Ciliatamide C (37).  37 was synthesized by the general 
procedure for amide coupling D starting from 34 (16 mg, 0.057 mmol) and 9-
decenoic acid (13, 10.6 μL, 0.06 mmol) to yield a pale yellow oil.  Yield: 81% 
(20.1 mg).  [α]D
20 +43 (c 0.10, MeOH); Rf 0.44 (9:1 DCM/MeOH); IR (neat) 3274, 
2926, 2854, 1655, 1527, 1492 cm-1; 1H NMR (CD3CN, 600 MHz, 25 °C): δ 7.20 
(m, 5H), 6.70 (bd, J = 7.1 Hz, 1H, NH), 6.10 (bs, 1H, NH), 5.83 (ddt, J = 17.1, 
10.3, 6.8 Hz, 1H), 5.40 (dd, J = 10.5, 5.5 Hz, 1H), 5.00 (dd,  J = 17.1, 1.6 Hz, 
1H), 4.92 (dt,  J = 10.3, 1.6 Hz, 1H), 4.21 (dt, J = 12.1, 6.8 Hz, 1H), 3.27 (dd, J = 
14.7, 5.5 Hz, 1H), 3.20 (m, 2H), 2.88 (m, 1H), 2.87 (s, 3H), 2.17 (td, J = 7.4, 4.4 
Hz, 2H), 2.11 (m, 1H), 2.03 (m, 2H), 1.83 (m, 2H), 1.60 (qd, J = 12.1, 5.7 Hz, 1H), 
1.33 (m, 4H), 1.26 (m, 2H), 1.22 (m, 2H), 1.11 (m, 2H); 13C NMR (CD3CN, 150 
MHz, 25 °C): δ 175.5, 171.9, 171.8, 140.9, 140.0, 130.6, 129.8, 127.8, 115.3, 
58.8, 51.2, 43.0, 35.2, 35.1, 34.6, 32.5, 30.6, 30.4, 30.31, 30.28, 29.1, 26.2, 22.9; 
LCMS, single peak, 3.300 min, ES-API: m/z 428.3 [M+H]+; HRMS (TOF, ES+) 
C25H37N3O3Na [M+Na]
+ calc'd 450.2733, found 450.2729. 
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N-methyl-((R)-piperid-2-one-3-ylamino-(S)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (R,S)-Ciliatamide C (38).  38 was synthesized by the general 
procedure for amide coupling D starting from 35 (156 mg, 0.57 mmol) and 9-
decenoic acid (13, 105 μL, 0.56 mmol) to yield a colorless oil.  Yield: 80% (193 
mg).  [α]D
20 –55 (c 0.10, MeOH); Rf 0.44 (9:1 DCM/MeOH); IR (neat) 3274, 2926, 
2854, 1655, 1527, 1492 cm-1; 1H NMR (CD3CN, 600 MHz, 25 °C): δ 7.20 (m, 
5H), 6.70 (bd, J = 6.9 Hz, 1H, NH), 6.11 (bs, 1H, NH), 5.83 (ddt, J = 17.1, 10.3, 
6.7 Hz, 1H), 5.40 (dd, J = 10.5, 5.5 Hz, 1H), 5.00 (dd,  J = 17.1, 1.5 Hz, 1H), 4.92 
(dt,  J = 10.3, 1.5 Hz, 1H), 4.21 (dt, J = 11.8, 6.8 Hz, 1H), 3.27 (dd, J = 14.6, 5.5 
Hz, 1H), 3.20 (m, 2H), 2.89 (m, 1H), 2.87 (s, 3H), 2.17 (td, J = 7.4, 4.0 Hz, 2H), 
2.10 (m, 1H), 2.03 (m, 2H), 1.83 (m, 2H), 1.60 (qd, J = 11.8, 5.3 Hz, 1H), 1.33 (m, 
4H), 1.26 (m, 2H), 1.22 (m, 2H), 1.11 (m, 2H); 13C NMR (CD3CN, 150 MHz, 25 
°C): δ 174.8, 171.3, 171.2, 140.2, 139.3, 130.0, 129.1, 127.2, 114.7, 58.2, 50.6, 
42.4, 34.5, 34.4, 33.9, 31.9, 29.9, 29.8, 29.7, 29.6, 28.5, 25.6, 22.2; LCMS, single 
peak, 3.304 min, ES-API: m/z 428.3 [M+H]+; HRMS (TOF, ES+) C25H37N3O3Na 
[M+Na]+ calc'd 450.2733, found 450.2737. 
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N-methyl-((R)-piperid-2-one-3-ylamino-(R)-oxo-3-phenylpropan-2-yl)dec-9-
enamide, (R,R)-Ciliatamide C (39).  39 was synthesized by the general 
procedure for amide coupling D starting from 36 (185 mg, 0.67 mmol) and 9-
decenoic acid (13, 124 μL, 0.67 mmol) to yield a pale yellow oil.  Yield: 98% (283 
mg).  [α]D
20 +56 (c 0.10, MeOH); Rf 0.44 (9:1 DCM/MeOH); IR (neat) 3274, 2926, 
2854, 1655, 1527, 1492 cm-1; 1H NMR (CD3CN, 600 MHz, 25 °C): δ 7.20 (m, 
5H), 6.77 (bs, 1H, NH), 6.18 (bs, 1H, NH), 5.83 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H), 
5.38 (dd, J = 10.7, 5.3 Hz, 1H), 4.99 (dd,  J = 17.0, 1.7 Hz, 1H), 4.92 (dt,  J = 
10.3, 1.7 Hz, 1H), 4.16 (dt, J = 11.7, 6.6 Hz, 1H), 3.26 (dd, J = 14.7, 5.3 Hz, 1H), 
3.21 (m, 2H), 2.88 (dd, J = 14.7, 10.7 Hz, 1H), 2.81 (s, 3H), 2.17 (m, 2H), 2.13 
(m, 1H), 2.02 (m, 2H), 1.83 (m, 2H), 1.64 (qd, J = 11.7, 5.1 Hz, 1H), 1.33 (m, 4H), 
1.26 (m, 2H), 1.22 (m, 2H), 1.11 (m, 2H); 13C NMR (CD3CN, 150 MHz, 25 °C): δ 
174.8, 171.13, 171.10, 140.2, 139.4, 129.9, 129.2, 127.2, 114.7, 58.4, 50.9, 42.4, 
34.43, 34.39, 33.9, 32.0, 29.9, 29.8, 29.7, 29.6, 28.4, 25.6, 22.1; LCMS, single 
peak, 3.301 min, ES-API: m/z 428.3 [M+H]+; HRMS (TOF, ES+) C25H37N3O3Na 
[M+Na]+ calc'd 450.2733, found 450.2733. 
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CHAPTER III 
 
TOTAL SYNTHESIS AND BIOLOGICAL EVALUATION OF 
8-EPI-LUCENTAMYCIN A AND ANALOGS 
 
 
Background 
 Recently, Fenical and co-workers reported on the isolation and 
characterization of four novel 3-methyl-4-ethylideneproline-containing peptides, 
Lucentamycins A-D (46-49), from the fermentation broth of a marine-derived 
actinomycete identified as Nocardiopsis lucentensis (Figure 5).8  Importantly, 
Lucentamycins A (46) and B (47) displayed significant in vitro cytotoxicity, with 
IC50 values of  0.2 μM and 11 μM, respectively, against HCT-116 human colon 
carcinoma.8 
 The structures of 46-49 were determined by a combination of 1D and 2D 
NMR techniques in addition to an advanced Marfey’s analysis.  For 46, 
interpretation of the data from the 1H NMR, 13C NMR, HSQC, COSY, TOCSY, 
and HMBC led to the determination of the presence and connectivity of leucine, 
homoarginine, benzoic acid, and the unprecedented 3-methyl-4-ethylideneproline 
moieties.  ROESY techniquies were employed to determine the relative 
stereochemistry of the substitutions on the proline unit.  ROESY correlations 
were used to determine the Z geometry of the olefin.  The correlations from the 
methyl proton to H-9 and from H-9 to the α-proton were used to determine the cis 
configuration of the proline residue.  Marfey’s analysis of the acid hydrolysates 
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was then used to determine the absolute stereochemistry as (2S,3R)-3-methyl-4-
ethylideneproline. 
Based on the biological activity of Lucentamycin A and the broad-
spectrum of biological activity (antibiotic, antifungal, kinase inhibition) of other 
agents derived from Nocardiopsis,8-11 a total synthesis campaign targeting 
Lucentamycin A (46) to provide sufficient material for biological evaluation 
seemed warranted.12  Moreover, the Lucentamycins were attractive as a target 
for our program in the synthesis of unnatural analogs coupled with biological 
evaluation and target elucidation.13-17 
 
 
Figure 5. Structures of Lucentamycins A-D (46-49) 
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Retrosynthesis 
 The retro-synthesis of Lucentamycin A (46) involved cleavage of the two 
amide bonds of the non-proteogenic amino acid, 3-methyl-4-ethylideneproline 
nucleus to afford L-leucine tert-butyl ester (50), the functionalized lysine (51), and 
unnatural proline (52) (Scheme 5).  The functionalized lysine was envisioned to 
arise by acylation and guanidation of L-lysine (53). The key non-proteogenic 3-
methyl-4-ethylideneproline (54) would be accessed through chiral vinyl 
aminosulfoxonium salt chemistry as reported by Gais, for which a single X-ray 
crystal of 54 was disclosed.18 
 
Scheme 5.  Retrosynthesis of Lucentamycin A (46) 
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Model System Study 
While synthetic effort was focused on the synthesis of 54, we initiated a 
model study en route to an unnatural congener (64) of Lucentamycin A, wherein 
the non-proteogenic 3-methyl-4-ethylideneproline 54 was replaced with natural L-
proline (Scheme 6) in order to evaluate potential racemization problems and to 
develop structure-activity-relationships for the cytotoxicity of 46 against HCT-116 
cells.  To begin the synthesis, Fmoc-protected L-proline (55) was coupled under 
HATU conditions with leucine tert-butyl ester 50 to provide the dipeptide (56) in 
99% yield.   Standard Fmoc deprotection with 5% piperidine in DMF delivered the 
key lower peptide (57) in quantitative yield.   L-lysine 53 was treated with N,N'-Di-
Boc-1H-pyrazole-1-carboxamidine (58) to provide the bis-N-Boc-protected 
arginine derivative (59) in 77% yield.19  Acylation with benzoyl chloride and 
hydrolysis employing LiOH afforded the northern fragment (61) in 62% yield over 
the two steps.  The coupling of peptide 57 to peptide 61 justified the model study, 
as our initial EDCI/HOBt/collidine coupling conditions generated >90% chemical 
yield, but a 39:61 ratio of the desired coupled product (62) to the epimerized 
coupled product (63).  The degree of racemization was determined by analytical 
LCMS and confirmed by 1H NMR.  At this point, we evaluated a variety of 
coupling reagents, additives and solvent/temperature conditions. These 
conditions included EDCI/HOBt/collidine, as discussed, TFFH/HOAt/collidine, 
and HATU/collidine with or without HOAt as an additive, at various temperatures.  
Ultimately, the conditions of HATU and collidine without HOAt proved optimal, 
generating a 92:8 ratio of 62:63 in yields exceeding 90% and readily separable 
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by column chromatography. A final global deprotection with 10% TFA in DCM 
afforded the unnatural analog (64) of Lucentamycin A in 60% yield.   We then 
evaluated its affect on an HCT-116 cell line in order to determine if the 
stereochemistry and functionality of the non-proteogenic 3-methyl-4-
ethylideneproline nucelus was critical for biological activity.   Thus, a standard 48 
hour cell viability assay was performed with 64 at five concentrations (0, 0.025 
μM, 0.1 μM, 0.4 μM, 2.0 μM and 10 μM) relative to podophyllotoxin as a positive 
control.20  The control performed as expected, providing an IC50 value of 0.03 
μM.   However, the unnatural, Lucentamycin A analog (64) had no affect on HCT-
116 cell viability up to 10 μM.  These data suggest that the the topology afforded 
by the natural product is essential for potent in vitro cytotoxicity (IC50 = 0.2 μM) of 
Lucentamycin A (46) against HCT-116 cells. 
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Scheme 6.  Lucentamycin A model study to deliver model system (64) 
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Synthesis of Non-Proteogenic Core 
 Attention now turned to the construction of the key non-proteogenic 3-
methyl-4-ethylideneproline (52). Application of the Gais protocol proved arduous, 
with difficult E/Z mixtures at multiple points along the 11 step sequence, 
ultimately resulting in complex chromatographic separations and even 
sophisticated reverse phase systems failed to deliver key intermediates in yields 
satisfactory for carrying forward en route to a total synthesis of 46.  At this point, 
we revised our retrosynthesis for 52, and we envisioned access to 52 by a 
titanium-mediated cycloisomerization reaction21 (Scheme 7) to afford bicycle 
(65), which would be derived from Garner’s aldehyde (66).  Key to the success of 
this route would be the ability to epimerize the α-carbon; however, this route 
would also enable the synthesis of the C8 epimer of Lucentamycin A, 8-epi-
lucentamycin A, and further construct SAR. 
 
 
Scheme 7.  Revised retrosynthesis of non-proteogenic core (52) 
 
 To begin the synthesis of proline 52, Garner’s aldehyde (66) smoothly 
undergoes a Wittig reaction providing olefin (67) in 83% yield (Scheme 8).22  
Deprotection with p-TsOH in MeOH affords alcohol (68), which is then converted 
to the corresponding oxazolidin-2-one (69) in 83% yield for the two steps. 
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Deprotonation with KHMDS and alkylation with propargyl mesylate (70) delivers 
ene-yne (71). A titanium-mediated cycloisomerization reaction delivers bicycle 
(65), which sets the methyl stereocenter and the relative regiochemistry of the 3-
methyl-4-ethylideneproline nucleus in 91% yield.21  Detailed nOe studies and 
historical accounts confirmed the stereochemical assignment.  Opening of the 
cyclic carbamate with methoxide generates methyl carbamate (72), which is 
oxidized to the aldehyde (73) in 98% yield. Finally, a buffered bleach oxidation of 
73 leads to the carboxylic acid (74), the epimer of the key non-proteogenic 3-
methyl-4-ethylideneproline (52) in 60% yield.  A double deprotonation/kinetic 
quench with AcOH failed to provide the desired carboxylic acid (75), affording 
only starting material 73 with no evidence of any epimerization. Alternative 
approaches to epimerize 73 met with similar unproductive results.23  Thus, our 
strategy adjusted to target the synthesis and biological evaluation of 8-epi-
Lucentamycin A employing 73.  However, removal of the methyl carbamate in 73 
proved equally challenging, and we were unable to affect this key transformation 
under a variety of reaction conditions.  These conditions included TMSI/DCM, 
TMSI/MP.Carbonate/DCM, sulphur anion nucleophiles in THF with different 
concentrations of HMPA.  Other conditions tested were, different bases 
(Ba(OH)2, LiOH, 
nBuLi), as well as different acids (TFA, HCl).  All of these 
conditions led either to decomposition or no reaction. 
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SCHEME 8. Synthesis of an epimeric non-proteogenic 3-methyl-4-
ethylideneproline (74) and attempts to epimerize to deliver desired carboxylic 
acid (75) 
 
 
Total Synthesis of 8-epi-Lucentamycin A 
 Based on these results, we again modified our approach for the total 
synthesis of 8-epi-Lucentamycin A.  As shown in (Scheme 9), bicycle (65) was 
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treated in a single pot with 3.0 M NaOH under microwave irradiation, followed by 
an in situ protection of the secondary amine to deliver Boc-protected pyrrolidine 
(76) in 80% yield (Scheme 9).24  Alcohol 76 smoothly underwent oxidation to the 
corresponding aldehyde (77) in 70% yield.  Repetition of the buffered bleach 
oxidation of 77 provided carboxyclic acid (78), the epimer of the key non-
proteogenic 3-methyl-4- ethylideneproline (52). The reaction delivered acid 78 
proceeded cleanly, therefore crude material (>95% pure) was carried forward into 
the coupling step.  The crude 78 was directly coupled to L-leucine tert-butyl ester 
(50) under HATU conditions (61% for two steps), followed by a chemoselective 
deprotection of the Boc group under anhydrous acidic conditions to deliver 
southern dipetide fragment (79) in 68% yield.25 
 
 
Scheme 9.  Synthesis of the key non-proteogenic 3-methyl-4-ethylideneproline 
(78) and southern dipeptide fragment (79) 
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 Dipeptides 79 and 61 were treated with our optimal coupling system of 
HATU and collidine in DMF/DCM at 0 oC to deliver protected tetrapeptide (80) in 
81% yield, as a 92:8 ratio of diastereomers.  After separation of the racemized 
material, a global deprotection employing 25% TFA in DCM provided 8-epi-
Lucentamycin A (81) in an unoptimized 47% yield (Scheme 10).  NMR data of 
the epimeric Lucentamycin A 81 agreed well with the natural product 46, with the 
expected exceptions due to the epimerization of C8. 
 
 
Scheme 10.  Total synthesis of 8-epi-Lucentamycin A (81) 
  
Biological Data 
 Lucentamycin A (46) displayed significant in vitro cytotoxicity, IC50 value of 
0.2 μM, against HCT-116 human colon carcinoma.   With 8-epi-lucentamycin A 
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(81) in hand, we evaluated its affect on an HCT-116 cell line in order to 
determine if the stereochemistry of the non-proteogenic 3-methyl-4-
ethylideneproline nucelus was critical for biological activity.   Thus, a standard 48 
hour cell viability assay was again performed with 64 and 81 at five 
concentrations (0, 0.025 μM, 0.1 μM, 0.4 μM, 2.0 μM and 10 μM) relative to 
podophyllotoxin as a positive control.20  The control performed as expected, 
providing an IC50 value of 0.03 μM.   However, the unnatural, epimeric 
Lucentamycin A (81) had no affect on HCT-116 cell viability up to 10 μM.   The 
cytotoxicity data generated with both 81 and 64 suggest that the stereochemistry 
at C8, and the topology afforded by the natural product, is essential for potent in 
vitro cytotoxicity (IC50 = 0.2 μM) of Lucentamycin A (46) against HCT-116 cells 
(Figure 6). 
 
 
Figure 6.  Cytotoxicity of Model System (64) and 8-epi-Lucentamycin A (81) 
against HCT-116 human colon carcinoma 
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Conclusions 
Thus, the first synthetic efforts towards the Lucentamycins A-D, 46-49, 
have been reported culminating in the total synthesis of 8-epi-Lucentamycin A 
(81).  The synthesis features a titanium-mediated cycloisomerization reaction to 
construct the key, epimeric, non-proteogenic 3-methyl-4-ethylideneproline 78. 
The convergent synthetic route afforded 8-epi-Lucentamycin A (81) in 15 steps, 
with 10 steps longest linear sequence, and an overall yield of 2.2%. Biological 
evaluation of 81 and another unnatural congener 64 indicated that both were 
inactive relative to natural 46, with an IC50 value of >10 μM in a HCT-116 human 
carcinoma cell line. Interestingly, these studies suggest that the natural 
configuration of the non-proteogenic 3-methyl-4-ethylideneproline (52) is 
essential for bioactivity. 
 
 
Figure 7.  Compounds synthesized that did not match natural product spectral 
data 
 
 
 
Within a day of our synthesis being published online a total synthesis of 
Lucentamycin A was also published.26  However the spectroscopic data from the 
synthetic Lucentamycin A did not match the natural product suggesting that the 
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natural product is actually an epimer of the reported structure.  Our labratory 
synthesized 81 while Del Valle, et. al. synthesized 46 (Figure 7).  Upon 
comparison of the NMR what was reported at the natural product did not match 
either synthetic compound and the molecules synthesized were found to have no 
biological activitiy.  Considering the facts that both 81 and 46 were synthesized, 
both were biologically inactive, and did not match the NMRs of the natural 
product, we determined that the natural product had been assigned the incorrect 
stereochemistry.  It is possible that the correct stereochemistry could be the 
opposite absolute stereochemistry at C-8 and C-9 than reported, the proline 
could have a trans configuration with the opposite configuration than 81, the 
olefin may possibly have an E configuration instead of Z, the homoarginene 
moiety could be assigned incorrectly, or some combination of all of the above.  
However, ROESY correlations supporting both the Z alkene and 2,3-cis 
substitution were observed for the natural Lucentamycin A.  These data suggest 
that the relative stereochemistry on the proline is correct and that it is only the 
absolute stereochemistry that was incorrectly reported. 
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Experimental Section 
General Experimental 
All 1H and 13C NMR spectra were recorded on 300 MHz, 400 MHz or 500 MHz 
instruments. Chemical shifts are reported in ppmrelative to residual solvent 
peaks as an internal standard set to δ 7.26 and δ 77.0 (CDCl3). Data are 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q =quartet, br = broad, m = multiplet), integration, coupling constant (Hz).   2-
Dimensional NMR spectra (NOESY and COSY) were obtained on a 500 
spectrometer (operating at 500.134 MHz for 1H and 124.996 MHz for 13C).  IR 
spectra were recorded as thin films and are reported in wavenumbers (cm-1). 
Low resolution mass spectra were obtained on an analytical LCMS with 
electrospray ionization. High resolution mass spectra were recorded on a Qtof-
API-US system. The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference. Analytical thin layer chromatography was 
performed on 250 μM silica gel 60 F254 plates. Visualization was accomplished 
with UV light, and/or the use of ninhydrin, anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on 
silica gel was performed using Silica Gel 60 (230- 400 mesh) from Sorbent 
Technologies. Analytical HPLC was performed on an analytical LCMS with UV 
detection at 214 nm and 254 nm along with ELSD detection. Chiral HPLC was 
performed on an analytical HPLC utilizing a Chiracel OD, OJ or Chiralpak AD 
columns (4.6 mm x 25 cm). Solvents for extraction, washing and chromatography 
were HPLC grade. All reagents were purchased and were used without 
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purification. All polymer-supported reagents were purchased. Flame-dried (under 
vacuum) glassware was used for all reactions. All reagents and solvents were 
commercial grade and purified prior to use when necessary. Mass spectra were 
obtained on a Q-TOF API-US mass spectrometer to acquire high-resolution 
mass spectrometry (HRMS) data. 
 
Experimental: 
 
 
 
(S)-(9H-fluoren-9-yl)methyl 2-((S)-1-tert-butoxy-4-methyl-1-oxopentan-2-
ylcarbamoyl)pyrrolidine-1-carboxylate (56).  N-Fmoc-L-Proline (101 mg, 0.3 
mmol), L-Leucine tert-butyl ester hydrochloride (67 mg, 0.3 mmol) and O-(7-
Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (171 
mg, 0.45 mmol) were added to a flame dried flask under argon.  The flask was 
evacuated and backfilled with argon three times.  Anhydrous DCM (1 mL), 
anhydrous DMF (0.5 mL), and collidine (79 µL, 0.6 mmol) were added in that 
order and stirred at room temperature for 3hr.  HCl (1 N, 1 mL) was added to 
quench the reaction.  The reaction mixture was diluted with DCM (3 mL) and 
washed with H2O (3 x 1.5 mL) and filtered through a phase separator.  The crude 
mixture was concentrated in vacuo and then purified by automated flash 
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chromatography (1:0 to 1:1 Hex:EtOAc) to yield the product as a white solid (151 
mg, 0.3 mmol) in 99% yield.  mp 154.9 °C; [α]D
20 -56 (c = 0.2, CHCl3); Rf 0.4 (1:1, 
EtOAc:Hex); IR (thin film) 3329, 2956, 2928, 1733, 1685, 1450, 1418, 1149 cm-1; 
1H NMR (500.1 MHz, MeOD) δ (ppm): 7.80 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.5 
Hz, 1H), 7.62 (dd, J = 35.2, 7.5 Hz, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.32 (t, J = 7.4 
Hz, 2H), 4.29 (m, 5H), 3.52 (m, 2H), 2.27 (m, 1H), 2.00 (m, 3H), 1.61 (m, 3H), 
1.44(d, J = 11.1 Hz, 9H), 0.93 (dd, J = 22.7, 6.6 Hz, 3H), 0.77 (dd, J = 30.6, 6.5 
Hz, 3H);  13C NMR (100.6 MHz, MeOD) δ (ppm): 175.2, 174.9, 173.3, 173.2, 
156.7, 156.5, 145.52, 145.47, 145.2, 144.9, 142.7, 142.6, 142.54, 142.46, 
128.90, 128.85, 128.82, 128.3, 128.20, 128.18, 126.4, 126.2, 121.0, 82.63, 
82.59, 69.2, 68.7, 61.4, 61.2, 53.1, 48.1, 41.5, 41.4, 32.7, 31.4, 28.2, 26.00, 
25..96, 25.3, 24.5, 23.3, 23.2, 22.0, 21.8; HRMS (TOF, ES+) C30H38N2O5Na 
[M+Na]+ calc'd 529.2678, found 529.2695 
 
 
 
(S)-tert-butyl 4-methyl-2-((S)-pyrrolidine-2-carboxamido)pentanoate (57).  56 
(101 mg, 0.2 mmol) was added to a flask and dissolved in a solution of 5% 
piperidine in DMF.  The mixture was stirred at room temperature for 0.5 hr.  The 
crude mixture was concentrated in vacuo and then purified by automated flash 
chromatography (1:0 to 9:1 DCM:MeOH) to yield the product as a white solid (57 
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mg, 0.2 mmol) in 100% yield.  Rf 0.17 (9:1, DCM:MeOH); IR (thin film) 3330, 
2958, 2871, 1735, 1671, 1508, 1368, 1150 cm-1; 1H NMR (500.1 MHz, MeOD) δ 
(ppm): 4.32 (dd, J = 8.2, 6.7 Hz, 1H), 3.67 (dd, J = 8.3, 5.7 Hz, 1H), 3.00 (m, 1H), 
2.90 (m, 1H), 2.13 (m, 1H), 1.77 (m, 3H), 1.65 (m, 1H), 1.59 (m, 2H), 1.45 (s, 
9H), 0.95 (d, J = 6.4 Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H);  13C NMR (100.6 MHz, 
MeOD) δ (ppm): 176.7, 173.2, 82.7, 61.4, 52.7, 48.1, 41.7, 32.2, 28.2, 26.9, 26.1, 
23.3, 21.9; HRMS (TOF, ES+) C15H29N2O3 [M+H]
+ calc'd 285.2178, found 
285.2169 
 
 
 
(S)-methyl 2-benzamido-6-(2,3-bis(tert-
butoxycarbonyl)guanidino)hexanoate (60).  To a solution of (2S)-2-Amino-6-
[N,N’-bis(tert-butoxycarbonyl)guanidino]hexanoic Acid Methyl Ester (99 mg, 0.25 
mmol) in anhydrous DCM (1 mL) and anhydrous DMF (0.5 mL) in a flame dried 
flask.  Collidine (35.8 µL, 0.27 mmol) and benzoyl chloride (27 µL, 0.23 mmol) 
were added in that order and stirred at room temperature for 1.5 hr.  HCl (1 N, 1 
mL) was added to neutralize the reaction.  The reaction mixture was diluted with 
DCM (3 mL) and washed with H2O (3 x 2 mL) and filtered through a phase 
separator.  The crude mixture was in vacuo and then purified by automated flash 
chromatography (1:0 to 0:1 Hex:EtOAc) to yield the product as a crusty foam (90 
mg, 0.18 mmol) in 72% yield.  mp 51.7 °C; [α]D
20 26 (c = 0.15, CHCl3); Rf 0.34 
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(1:1, EtOAc:Hex); IR (thin film) 3331, 2926, 2854, 1722, 1642, 1156, 1135, 738 
cm-1; 1H NMR (600.1 MHz, MeOD) δ (ppm): 7.84 (m, 2H), 7.54 (t, J = 7.4 Hz, 
1H), 7.46 (t, J = 7.5 Hz, 2H), 4.60 (dd, J = 9.5, 5.1 Hz, 1H), 3.74 (s, 3H), 3.37 (t, J 
= 7.0 Hz, 2H), 1.98 (m, 1H), 1.87 (m, 1H), 1.63 (m, 2H), 1.53 (m, 2H), 1.49 (s, 
9H), 1.45 (s, 9H);  13C NMR (150.9 MHz, MeOD) δ (ppm): 174.3, 170.5, 164.6, 
157.6, 154.2, 135.2, 132.9, 129.6, 128.5, 84.4, 80.4, 54.3, 52.7, 41.4, 31.9, 29.6, 
28.6, 28.2, 24.4; HRMS (TOF, ES+) C25H38N4O7Na [M+Na]
+ calc'd 529.2638, 
found 529.2663 
 
 
 
(S)-2-benzamido-6-(2,3-bis(tert-butoxycarbonyl)guanidino)hexanoic acid 
(61).  60 (90 mg, 0.18 mmol) was added to a flask and dissolved in THF (1.6 
mL), and MeOH (0.4 mL).  A solution of LiOH (17 mg, 0.71 mmol) in H2O (0.4 
mL) was then added to the reaction, which was then stirred at room temperature 
for 4 hrs.  HCl (0.5 N) was added to bring the mixture to pH 4.  The aqueous 
layer was extracted with DCM (3 x 3 mL), the combined organic layers were 
filtered through a phase separator.  The crude mixture was concentrated in 
vacuo and then purified by automated flash chromatography (1:0 to 9:1 
DCM:MeOH) to yield the product as a crusty foam (76 mg, 0.15 mmol) in 85% 
yield.  [α]D
20 31.7 (c = 0.2, CHCl3); Rf 0.23 (9:1, DCM:MeOH); IR (thin film) 3330, 
2979, 2935, 1722, 1641, 1615, 1368, 1332, 1154, 1135 cm-1; 1H NMR (600.1 
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MHz, MeOD) δ (ppm): 7.85 (m, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 
2H), 4.91 (brs, 1H), 4.60 (dd, J = 9.5, 4.6 Hz, 1H), 3.37 (t, J = 7.1 Hz, 2H), 2.01 
(m, 1H), 1.88 (m, 1H), 1.64 (m, 2H), 1.53 (m, 2H), 1.48 (s, 9H), 1.45 (s, 9H);  13C 
NMR (150.9 MHz, MeOD) δ (ppm): 175.6, 170.4, 164.2, 157.5, 154.1, 135.3, 
132.8, 129.5, 128.5, 84.5, 80.5, 54.2, 41.6, 32.1, 29.7, 28.6, 28.2, 24.5; HRMS 
(TOF, ES+) C24H37N4O7 [M+H]
+ calc'd 493.2662, found 493.2664 
 
 
(S)-tert-butyl 2-((S)-1-((S)-2-benzamido-6-(2,3-bis(tert-
butoxycarbonyl)guanidino)hexanoyl)pyrrolidine-2-carboxamido)-4-
methylpentanoate (62).  57 (14.2 mg, 0.05 mmol) and 61 (24.6 mg, 0.05 mmol), 
in anhydrous DCM (0.2 mL each), were added to a flame dried flask under argon 
via syringe.  Anhydrous DMF (0.2 mL) was added and the solution was cooled to 
0 °C.  O-(7-Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium 
hexafluorophosphate (28.5 mg, 0.075 mmol) was added followed by collidine (7.3 
µL, 0.055 mmol).  The reaction was stirred at 0 °C for 4.5 hr and then diluted with 
DCM (3 mL) and washed with H2O (3 x 1.5 mL) and filtered through a phase 
separator.  The crude mixture was concentrated in vacuo and then purified by 
automated flash chromatography (1:0 to 0:1 Hex:EtOAc) to yield the product as a 
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crusty foam (34.2 mg, 0.045 mmol) in 90% yield.  [α]D
20 -57 (c = 0.2, CHCl3); Rf 
0.53 (EtOAc); IR (thin film) 3330, 2976, 1720, 1637, 1418, 1368, 1331, 1155, 
1134 cm-1; 1H NMR (600.1 MHz, MeOD) δ (ppm): 7.85 (m, 2H), 7.53 (m, 1H), 
7.45 (m, 2H), 4.80 (dd, J = 9.5, 4.8 Hz, 1H), 4.49 (dd, J = 8.5, 4.3 Hz, 1H), 4.60 
(dd, J = 9.5, 4.6 Hz, 1H), 4.27 (t, J = 7.6 Hz, 1H), 3.94 (m, 1H), 3.74 (m, 1H), 
3.39 (m, 2H),  2.22 (m, 1H), 2.10 (m, 1H), 2.03 (m, 2H), 1.94 (m, 1H), 1.84 (m, 
1H), 1.76 (m, 1H), 1.66 (m, 2H), 1.56 (m, 4H), 1.49 (s, 9H), 1.450 (s, 9H), 1.447 
(s, 9H), 0.95 (d, J = 6.6 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H);  13C NMR (100.6 MHz, 
MeOD) δ (ppm): 174.2, 173.4, 173.1, 170.3, 164.6, 157.6, 154.2, 135.1, 132.8, 
129.5, 128.6, 84.4, 82.5, 80.3, 61.2, 53.3, 53.1, 48.7, 41.6, 41.5, 31.8, 30.5, 29.8, 
28.6, 28.3, 28.2, 26.0, 25.9, 24.2, 23.3, 22.1; HRMS (TOF, ES+) C39H63N6O9 
[M+H]+ calc'd 759.4657, found 759.4659 
 
 
 
(S)-2-((S)-1-((S)-2-benzamido-6-guanidinohexanoyl)pyrrolidine-2-
carboxamido)-4-methylpentanoic acid (64). 63 (36.9 mg, 0.05 mmol) was 
added to a flask and a stock solution of 20 % TFA in DCM and stirred under 
argon for 18 h.  MeOH was added to the reaction mixture which was then 
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concentrated in vacuo.  More MeOH was added and the reaction concentrated 
again.  Because of the high polarity of the compound, the product was purified by 
reverse phase preparatory HPLC to yield the product as a light yellow oil (14.7 
mg, 0.03 mmol) in 60 % yield.   Rf 0.025 (9:1, DCM:MeOH); 
1H NMR (600.1 MHz, 
DMSO-d6) δ (ppm): 10.47 (m, 1H), 8.42 (d, J = 7.2 Hz, 1H), 7.87 (m, 2H), 7.52 (t, 
J = 7.4 Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 6.98 (m, 3H), 4.81 (m, 1H), 4.20 (dd, J = 
8.9, 2.5 Hz, 1H), 3.83 (q, J = 6.6 Hz, 1H), 3.75 (dd, J = 7.8, 5.5 Hz, 2H), 3.32 
(brs, 2H), 3.12 (m, 1H), 3.03 (m, 1H), 1.98 (m, 3H), 1.84 (m, 2H), 1.66 (m, 2H), 
1.58 (m, 3H), 1.50 (m, 1H), 1.44 (m, 2H), 1.37 (m, 1H), 0.86 (d, J = 6.6 Hz, 3H), 
0.85 (d, J = 6.6 Hz, 3H);  13C NMR (150.9 MHz, DMSO-d6) δ (ppm): 175.9, 170.8, 
169.7, 165.8, 157.2, 133.7, 131.4, 128.2, 127.5, 61.3, 52.4, 51.0, 47.0, 42.8, 
41.2, 31.5, 29.4, 28.6, 24.6, 24.3, 23.0, 22.9, 22.8; HRMS (TOF, ES+) 
C25H39N6O5 [M+H]
+ calc'd 503.2982, found 503.2976 
 
 
 
(R)-tert-butyl 2,2-dimethyl-4-vinyloxazolidine-3-carboxylate (67).  To a 
suspension of Ph3P
+CH3Br
− (11.5 g, 32.189 mmol) in THF (268 mL) was added 
n-BuLi (2 M, 17.4 mL, 34.872 mmol). The deep red solution was stirred at 0 °C 
for 1 h. Then, a solution of Garner’s aldehyde 66 (6.15 g, 26.824 mmol) in THF 
(15 ml) was added dropwise at 0 °C.  The red solution was warmed to room 
temperature and stirred for 12 h. After complete consumption of starting material 
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by TLC analysis (KMnO4, Rf = 0.61; 3:1 hexanes:EtOAc), hexanes was added to 
the reaction mixture in 4:1 (v:v) ratio. The suspension was filtered through Celite 
and concentrated. Purification by flash chromatography (10:1 hexanes-ethyl 
acetate on silica gel) gave the desired vinyloxazolidine 67 (4.86 g, 83%) as a 
pale yellow oil.  [α]D
20 +16.29 (c = 0.032, CHCl3); IR 2980, 2935, 1699, 1384, 
1091, 860 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 5.79 (ddd; J=17.2, 10.2, 5.2 
Hz; CH=CH2; 1H), 5.08 (d; J=16.8 Hz; CH=CH2; 1H), 4.97 (d; J=10.0 Hz; 
CH=CH2; 1H), 4.14 (bs; CH-N; 1H), 3.72 (dd; J=8.8, 2.0 Hz; CH2-O-; 1H), 3.50 
(dd; J=8.4, 2.0 Hz; CH2-O-; 1H), 1.66 (s; CH3; 3H), 1.53 (s; CH3; 3H), 1.40 (s, 
C(CH3)3; 9H); 
13C NMR (100 MHz, CDCl3, δ (ppm)): 152.40, 138.68, 115.69, 
94.57, 79.67, 68.66, 60.37, 28.89, 27.48, 24.82; HRMS (TOF, ES+) 
C12H22NO3Na [M+Na]
+ calc'd 228.1600, found 228.1602. 
 
 
 
(R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate (68). To a solution of 
vinyloxazolidine 67 (1.50 g, 6.599 mmol) in MeOH (66.0 mL) was added p-
toluenesulfonic acid monohydrate (0.628 g, 3.300 mmol) as a solid addition at 0 
°C. The mixture was slowly warmed to room temperature and stirred for 12 h. 
After complete consumption of starting material by TLC analysis (KMnO4, Rf = 
0.35; 1:1 hexanes:EtOAc), the reaction mixture was concentrated and the 
residue was diluted with ethyl acetate (50 mL).  The organic layer was 
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transferred to a separatory funnel and washed with saturated sodium bicarbonate 
solution (3 X 20 mL). The organic phase was dried over MgSO4, filtered, and 
concentrated to give the desired amino alcohol 68 (0.93 g, 75%) as a pale yellow 
oil.  [α]D
20 +24.05 (c = 0.017, CHCl3); IR 3344, 2998, 2932, 1692, 1522, 1366, 
1171, 1053 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 5.79 (ddd; J=17.2, 10.2, 
5.2 Hz; CH=CH2; 1H), 5.25 (dd; J=18.8, 1.2 Hz; CH=CH2; 1H), 5.21 (dd; J=11.6, 
1.2 Hz; CH=CH2; 1H), 4.99 (d; J=7.6 Hz; NH; 1H), 4.21 (bs; CH-N; 1H), 3.68 (d; 
J=11.2, 4.4 Hz; CH2-OH; 1H), 3.60 (d; J=11.2, 5.6 Hz; CH2-OH; 1H), 2.53 (bs; 
OH; 1H), 1.43 (s, C(CH3)3; 9H);  
13C NMR (100 MHz, CDCl3, δ (ppm)): 156.26, 
135.69, 116.65, 80.05, 65.29, 54.90, 50.86, 28.55; HRMS (TOF, ES+) 
C9H17NO3Na [M+Na]
+ calc'd 210.1106, found 210.1108. 
 
 
 
(R)-4-vinyloxazolidin-2-one (69). To a solution of amino alcohol 68 (2.29 g, 
12.230 mmol) in THF (245 mL) was added thionyl chloride (7.1 mL, 97.842 
mmol) dropwise at 0 °C. The resulting mixture was slowly warmed to room 
temperature and stirred for 12 h. After complete consumption of starting material 
by TLC analysis (KMnO4, Rf = 0.17; 1:1 hexanes:EtOAc), the solvent was 
removed under reduced pressure. The remaining brown residue was purified by 
Biotage chromatography to give the desired vinyloxazolidin-2-one 69 (1.07 g, 
78%) as a yellow oil.  [α]D
20 +20.32 (c = 0.017, CHCl3); IR 3281, 2918, 2850, 
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1745, 1397, 1232, 931 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 6.04 (bs; NH; 
1H), 5.82 (ddd; J=17.2, 10.4, 7.2 Hz; CH=CH2; 1H), 5.32 (d; J=16.8 Hz; CH=CH2; 
1H), 5.25 (d; J=10.0 Hz; CH=CH2; 1H), 4.53 (dd; J=8.8, 8.4 Hz; CH2-O; 1H), 4.38 
(ddd; J=7.6, 7.6, 7.6, Hz; CH-NH; 1H),  4.06 (dd; J=8.8, 8.4 Hz; CH2-O; 1H);  
13C 
NMR (100 MHz, CDCl3, δ (ppm)): 159.90, 135.90, 18.89, 70.17, 55.45; HRMS 
(TOF, ES+) C5H8NO2 [M+H]
+ calc'd 114.0555, found 114.0558. 
 
 
 
(R)-3-(but-2-ynyl)-4-vinyloxazolidin-2-one (71). To a solution of vinyloxazolidin-
2-one 69 (0.250 g, 2.210 mmol) in DMF (22.1 mL) was added potassium 
bis(trimethylsilyl)amide (KHMDS, 0.5 M, 5.3 mL, 2.652 mmol) dropwise at 0 °C. 
After stirring for 10 min at 0 °C, propargyl mesylate 70 (0.491 g, 3.315 mmol) in 
DMF (2 mL) was added at 0 °C. The resulting mixture was slowly warmed to 
room temperature and stirred for 4 h. The reaction mixture was quenched with 
water (5:1 water/DMF (v:v)) and diluted with ethyl acetate. The aqueous layer 
was extracted with ethyl acetate (3 X 25 mL). The combined organic phases 
were washed with water (3 X 10 mL), dried over MgSO4, filtered, and 
concentrated. Purification by Biotage chromatography gave the desired 3-(but-2-
ynyl)-4-vinyloxazolidin-2-one 71 (0.310 g (85%) as a colorless oil.  [α]D
20 -18.63 
(c = 0.03, CHCl3); IR 3085, 2985, 2921, 2292, 2236, 1447, 1439 1352, 1248, 
1177, 939 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 5.69 (ddd; J=16.8, 10.0, 8.4 
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Hz; CH=CH2; 1H), 5.45 (d; J=16.8 Hz; CH=CH2; 1H), 5.40 (d; J=10.6 Hz; 
CH=CH2; 1H), 4.47 (dd; J=8.8, 8.0 Hz; CH2-O; 1H), 4.39 (ddd; J=8.4, 8.0, 8.0, 
Hz; CH-N; 1H), 4.29 (dq, J=15.2, 2.4 Hz; N-CH2-C≡C; 1H) 3.97 (dd; J=8.0, 7.6 
Hz; CH2-O; 1H). 3.59 (dq; J=17.2, 2.4 Hz; N-CH2-C≡C; 1H), 1.81 (t; J=2.0 Hz; 
C≡C-CH3; 3H); 
13C NMR (100 MHz, CDCl3, δ (ppm)): 157.73, 134.04, 121.93, 
80.79, 72.28, 67.29, 58.30, 32.32, 3.56; HRMS (TOF, ES+) C9H11NO2Na 
[M+Na]+ calc'd 188.0687, found 188.0689. 
 
 
 
(7R, 7aR, Z)-6-ethylidene-7-methyltetrahydropyrrolo[1,2-c]oxazol-3(1H)-one 
(65). A 125 mL, three-neck, round bottom flask was fitted with an internal 
thermometer and a 50 mL addition funnel.  The flask was charged with a solution 
of Ti(OiPr)4 (2.4 mL, 8.257 mmol) in Et2O (23.6 mL).  The addition funnel was 
charged with a solution of 3-(but-2-ynyl)-4-vinyloxazolidin-2-one 71 (0.310 g, 
1.877 mmol) in Et2O (37.5 mL). The entire apparatus was placed in a CyroCool 
bath set to -78 °C and the solution was chilled until the internal temperature 
reached -78 °C.  Cyclopentyl magnesium bromide (2.0 M, 8.3 mL, 16.514 mmol) 
was added slowly dropwise via syringe to the titanium solution, ensuring the 
internal temperature never rose above -70 °C.  After 30 min, the solution of 3-
(but-2-ynyl)-4-vinyloxazolidin-2-one 71 was added via addition funnel over 20 
minutes, keeping the internal temperature below -70 °C during the addition. The 
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mixture was stirred for 30 min at -70 °C, then warmed to -50 °C over 30 min and 
stirred for 5 h at -50 °C. The reaction mixture was quenched with saturated 
NH4Cl solution (10 mL) and diluted with EtOAc (20 mL). The aqueous layer was 
extracted with EtOAc and the combined organic phases were washed with water 
(2 X 10 mL), dried over MgSO4, filtered, and concentrated. Purification by 
Biotage chromatography gave the desired ethylideneproline 65 (0.220 g, 91%) as 
a colorless oil.  [α]D
20 +78.06 (c = 0.05, CHCl3); IR 2923, 2872, 1754, 1456, 1394, 
1203, 977, 775 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 5.26-5.18 (m; 
CH=CR2; 1H), 4.34 (dd; J=8.8, 7.6 Hz; CH2-O-; 1H), 4.13 (d; J=15.6 Hz; N-CH2; 
1H), 4.07 (dd; J=9.2, 2.4 Hz; CH2-O; 1H), 3.70 (d; J=15.2 Hz; N-CH2; 1H), 3.30 
(ddd; J=10.0, 7.2, 2.4 Hz; CH-NR2; 1H), 2.21-2.12 (m; CH-CH3; 1H), 1.52 (d; 
J=6.8 Hz; CH3-CH=CR2; 3H), 0.96 (d; J=6.4 Hz; CH-CH3; 3H); 
13C NMR (100 
MHz, CDCl3, δ (ppm)): 161.50, 140.99, 116.80, 66.51, 65.35, 48.48, 42.24, 
13.93, 13.10; HRMS (TOF, ES+) C9H14NO2 [M+H]
+ calc'd 168.1025, found 
168.1026. 
 
 
 
(2R, 3R, Z)-methyl 4-ethylidene-2-(hydroxymethyl)-3-methylpyrrolidine-1-
carboxylate (72). In a 250 mL round bottom flask under argon fitted with a 
stirbar, sodium metal (Na°, 2.8 g, 122.60 mmol) was treated at 0 °C with dry 
MeOH (120 mL).  The solvent became cloudy and was stirred for 1 h at 0 °C until 
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the entire mass of sodium metal was dissolved.  A solution of ethylideneproline 
65 (410 mg, 2.45 mmol) in MeOH (5 mL) was added dropwise to the solution.  
The resulting pale yellow solution was stirred at room temperature for 12-16 h.  
The solvent was concentrated and the residue was diluted with EtOAc (100 mL).  
The organic phase was washed with saturated NH4Cl solution (2 X 25 mL) and 
with brine (1 X 25 mL), dried over MgSO4, filtered and concentrated to give a 
pale yellow residue.  The residue was purified by silica gel chromatography (5:1 
hexanes/EtOAc then 3:1 hexanes/EtOAc) to provide the desired ethylidene-2-
(hydroxymethyl)-3-methylpyrrolidine-1-carboxylate 72 (422 mg, 86%)  as a 
colorless oil.  [α]D
20 +28.83 (c = 0.04, CHCl3); IR 3431, 2958, 2869, 1698, 1454, 
1393, 1062 cm-1; 1H NMR (400 MHz @ 342K C6D6, δ (ppm)):  5.06-5.00 (m; CH3-
CH=CR2; 1H), 4.02 (app d; J=14.8 Hz; CH2-OH; 1H), 3.81 (app d; J=15.2 Hz; 
CH2-OH; 1H), 3.63-3.57 (m; N-CH2; N-CH-CH2; 2H), 3.53 (dd; J=10.4, 5.2 Hz; N-
CH2; 1H), 3.49 (s; CO2CH3; 3H), 2.34-2.16 (m; CH3-CH; 1H), 1.32 (dd; J=6.8, 1.2 
Hz; CH3-CH=CR2; 3H), 0.89 (d; J=7.2 Hz; CH3-CH; 3H); 
13C NMR (100 MHz @ 
342K, C6D6, δ (ppm)): 156.47, 140.69, 115.40, 67.67, 64.83, 51.76, 48.04, 40.26, 
29.69, 13.57; HRMS (TOF, ES+) C10H18NO3 [M+H]
+ calc'd 200.1287, found 
200.1284. 
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(2R, 3R, Z)-methyl 4-ethylidene-2-formyl-3-methylpyrrolidine-1-carboxylate 
(73). To a solution of ethylidene-2-(hydroxymethyl)-3-methylpyrrolidine-1-
carboxylate 72 (73 mg, 0.37 mmol) in DMSO (dry, 0.92 mL) was added NEt3 
(0.32 mL, 1.21 mmol) immediately followed by SO3·pyridine (192 mg, 2.31 mmol) 
in DMSO (0.93 mL).  The resulting yellow-orange solution was stirred at room 
temperature for 30 min. The reaction was quenched with 2 N HCl and extracted 
three times with EtOAc (3 X 15 ml). The organic layer was washed with 2 N HCl 
(1 X 10 ml), saturated NaHCO3 solution (3 X 15 mL), and brine solution (1 X 10 
mL).  The organic layer was dried over MgSO4, filtered and concentrated. The 
residue was purifed by column chromatography (5:1 hexanes/EtOAc then 3:1 
hexanes/EtOAc on silica gel) to provide the desired aldehyde 73 (70.1 mg, 98%) 
as a pale yellow oil.  IR 2961, 2870, 1703, 1698, 1451, 1070, 771 cm-1; 1H NMR 
(400 MHz, CDCl3, δ (ppm)): 9.56-9.43 (m; CHO; 1H), 5.36-5.29 (m; CH3-
CH=CR2; 1H), 4.25-4.04 (m; CH-CHO and N-CH2; 3H), 3.81-3.68 (m; CO2CH3; 
3H), 2.78-2.66 (m; CH3-CH; 1H), 1.65-1.56 (m; CH3-CH=CR2; 3H), 1.18 (d; J=6.8 
Hz; CH3-CH; 3H); 
13C NMR (100 MHz, CDCl3, δ (ppm)):  198.69, 156.18, 139.07, 
117.47, 66.31, 52.79, 48.06, 39.40, 20.94, 14.44; HRMS (TOF, ES+) C10H16NO3 
[M+H]+ calc'd 198.1130, found 198.1130. 
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(2R, 3R, Z)-4-ethylidene-1-(methoxycarbonyl)-3-methylpyrrolidine-2-
carboxylic acid (74). To a stirring solution of aldehyde 73 (70 mg, 0.36 mmol) in 
tBuOH (2 mL) was added 2-methyl-2-butene (1 mL).  In a separate vial, 
NaH2PO4 (460 mg, 3.34 mmol) and NaO2Cl (212 mg, 2.34 mmol) were added 
and dissolved in water (2 mL).  The tBuOH solution was cooled to 0 C and the 
bleach solution was added dropwise.  The resulting yellow solution was stirred at 
0 C for 2 h then quenched with saturated Na2S2O3 solution (5 mL) and acidified 
to pH 2.  The aqueous solution was extracted with EtOAc (3 X 25 mL) and dried 
over MgSO4, filtered and concentrated. The remaining residue was dissolved in 
methanolic ammonia (pH 9) and passed through a strong cation exchange (SCX) 
column.  Elution of the carboxylic acid 74 was performed using methanolic HCl 
(pH 1, Note: See General Methods section for exact procedure).  The methanolic 
solution was concentrated and redissolved in EtOAc (5 mL) and washed with 
water (2 mL).  The organic layer was dried over MgSO4, filtered and concentrated 
to provide the desired carboxylic acid 74 (59 mg, 78%) as a yellow foam.  IR 
3136, 3043, 1709, 1403 cm-1; 1H NMR (400 MHz, CDCl3, δ (ppm)): 10.53 (bs; 
CO2H; 1H), 5.35-5.33 (m; CH3-CH=CR2; 1H), 4.24-3.98 (m; CH-CO2H and N-
CH2; 3H), 3.74-3.70 (m; CO2CH3; 3H), 2.94-2.82 (m; CH3-CH; 1H), 1.59-1.57 (m; 
CH3-CH=CR2; 3H), 1.23-1.21 (m; CH3-CH; 3H); 
13C NMR (100 MHz, CDCl3, δ 
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(ppm)): 176.89, 156.60, 139.38, 117.57, 66.11, 53.23, 48.56, 29.84, 20.90, 
14.32; HRMS (TOF, ES+) C10H16NO4 [M+H]
+ calc'd 214.1079, found 214.1078. 
 
 
 
(2R,3R,Z)-tert-butyl 4-ethylidene-2-(hydroxymethyl)-3-methylpyrrolidine-1-
carboxylate (76).  65 (98.3 mg, 0.59 mmol), was added to a microwave vial and 
dissolved in dioxane (3.75 mL).  NaOH (3N, 1.47 mL, 4.41 mmol) was then 
added.  The vial was then irradiated for 1.5 hrs to a temperature of 110 °C.  The 
vial was then cooled to 0 °C and Boc2O (307.9 mg, 1.41 mmol) dissolved in 
dioxane (3.75 mL) was then added dropwise.  The reaction was stirred at 0 °C for 
2 hr and then neutralized with citric acid (10%).  H2O (10 mL) was added and the 
mixture was extracted with EtOAc (3 x 20 mL).  The combined organic layers 
were then dried (MgSO4), filtered, and concentrated in vacuo and then purified by 
flash chromatography (1:0 to 2:1 Hex:EtOAc) to yield the product as an oil (112.8 
mg, 0.48 mmol) in 79.5 % yield.  [α]D
20 22.4 (c = 0.2, CHCl3); Rf 0.40 (2:1, 
Hex:EtOAc); IR (thin film) 3417, 2967, 2924, 2869, 1699, 1673, 1407, 1366, 
1172, 1120 cm-1; 1H NMR (600.1 MHz, CDCl3, 40 °C) δ (ppm): 5.26 (m, 1H), 4.03 
(m, 1H), 3.85 (d, J = 15.4 Hz, 1H), 3.57 (m, 2H), 3.48 (m, 1H), 2.29 (brs, 1H), 
1.56 (m, 3H), 1.44 (d, J = 3.1 Hz, 9H), 1.09 (m, 3H);  13C NMR (150.9 MHz, 
CDCl3, 40 °C) δ (ppm): 156.6, 140.2, 115.8, 80.2, 67.3, 66.0, 48.4, 40.3, 28.4, 
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17.8, 14.1; HRMS (TOF, ES+) C13H24NO3 [M+H]
+ calc'd 242.1756, found 
242.1757 
 
 
 
(2R,3R,Z)-tert-butyl 4-ethylidene-2-formyl-3-methylpyrrolidine-1-carboxylate 
(77).  To a solution of 76 (102 mg, 0.42 mmol) in anhydrous DMSO (1.06 mL) 
was added NEt3 (0.37 mL, 2.66 mmol) immediately followed by SO3·pyridine 
(222 mg, 1.39 mmol) in anhydrous DMSO (1.07 mL).  The resulting yellow-
orange solution was stirred at room temperature for 30 min. The reaction was 
neutralized with 2 N HCl and extracted with EtOAc (3 X 15 ml). The organic layer 
was washed with brine solution (1 X 10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography (1:0 to 
4:1 Hex:EtOAc) to yield the product as an oil (70.6 mg, 0.30 mmol) in 69.7 % 
yield.  [α]D
20 92.4 (c = 0.2, CHCl3); Rf 0.72 (2:1, Hex:EtOAc); IR (thin film) 2974, 
2928, 2869, 1737, 1702, 1396, 1368, 1172, 1124 cm-1; 1H NMR (600.1 MHz, 
CDCl3, 50 °C) δ (ppm): 9.42 (m, 1H), 5.31 (m, 1H), 4.07 (m, 2H), 3.63 (m, 1H), 
2.67 (m, 1H), 1.60 (d, J = 7.0 Hz, 3H), 1.43 (m, 9H), 1.14 (d, J = 6.8 Hz, 3H);  13C 
NMR (150.9 MHz, CDCl3, 50 °C) δ (ppm): 198.8, 154.2, 138.4, 116.9, 81.0, 71.9, 
48.3, 39.3, 28.2, 15.9, 14.3; HRMS (TOF, ES+) C13H22NO3 [M+H]
+ calc'd 
240.1600, found 240.1599. 
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(2R,3R,Z)-tert-butyl 2-((S)-1-tert-butoxy-4-methyl-1-oxopentan-2-
ylcarbamoyl)-4-ethylidene-3-methylpyrrolidine-1-carboxylate (82):  To a 
stirring solution of 77 (49.2 mg, 0.21 mmol) in tBuOH (1.5 mL) was added 2-
methyl-2-butene (0.75 mL).  In a separate vial, NaH2PO4 (267 mg, 1.93 mmol) 
and NaO2Cl (123 mg, 1.36 mmol) were added and dissolved in water (1.5 mL).  
The tBuOH solution was cooled to 0 C and the bleach solution was added 
dropwise.  The resulting yellow solution was stirred at 0 C for 2 hr then 
quenched with saturated Na2S2O3 solution until cloudy and acidified to pH 4.  The 
aqueous solution was extracted with EtOAc (3 X 25 mL) and dried over MgSO4, 
filtered and concentrated in vacuo.  The crude product was then dissolved in 
anhydrous DCM (1 mL) and DMF (1 mL) under argon.  L-Leucine tert-butyl ester 
hydrochloride (46.0 mg, 0.21 mmol), O-(7-Azabenzotriazol-1-yl)-N,N,N,N-
tetramethyluronium hexafluorophosphate (117 mg, 0.31 mmol), and collidine 
(54.6 µL, 0.41 mmol) were added in that order and stirred at room temperature 
for 3hr.  HCl (1N) was added to neutralize the reaction.  The reaction mixture was 
diluted with DCM (10 mL) and washed with H2O (3 x 5 mL) and filtered through a 
phase separator.  The crude mixture was concentrated in vacuo and then purified 
by automated flash chromatography (1:0 to 4:1 Hex:EtOAc) to yield the product 
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as a crusty foam (52.9 mg, 0.12 mmol) in 61 % yield.  [α]D
20 36.8 (c = 0.2, 
CHCl3); Rf 0.48 (4:1, Hex:EtOAc); IR (thin film) 3279, 2963, 2929, 1743, 1704, 
1656, 1385, 1371, 1145 cm-1; 1H NMR (600.1 MHz, CDCl3, 35 °C) δ (ppm): 6.37 
(m, 1H), 5.30 (m, 1H), 4.46 (m, 1H), 4.20 (brs, 1H), 3.99 (d, J = 14.6 Hz, 1H), 
3.84 (brs, 1H), 2.88 (brs, 1H), 1.66 (m, 1H), 1.58 (m, 4H), 1.44 (m, 9H), 1.41 (m, 
9H), 1.17 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H) , 0.91 (d, J = 6.7 Hz, 3H);  
13C NMR (150.9 MHz, CDCl3, 35 °C) δ (ppm): 171.8, 171.5, 155.0, 139.0, 116.6, 
81.6, 80.6, 68.3, 51.1, 47.9, 43.6, 42.1, 28.3, 27.9, 24.8, 22.8, 22.0, 19.6, 14.4; 
HRMS (TOF, ES+) C23H41N2O5 [M+H]
+ calc'd 425.3015, found 425.3015 
 
 
 
(S)-tert-butyl 2-((2R,3R,Z)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-
4-methylpentanoate (79).  82 (50.8 mg, 0.12 mmol) was added to a small vial 
and placed under argon.  Anhydrous EtOAc (0.45 mL) and anhydrous HCl in 
dioxane (4 M, 0.15 mL, 0.6 mmol) were then added and the reaction was stirred 
for 1 hr.  Additional anhydrous EtOAc (0.45 mL) and anhydrous HCl in dioxane (4 
M, 0.15 mL, 0.6 mmol) were then added at 1 hr, 2 hr, and 4 hr total reaction time 
for a total of four injections of each EtOAc and HCl in dioxane.  NaOH (1 N) was 
added to neutralize the reaction.  The aqueous layer was separated an extracted 
with EtOAc (3 x 5 mL).  The combined organic layers were dried over MgSO4, 
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filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (1:0 to 19:1 DCM:MeOH) to yield the product as an oil (26.2 mg, 
0.081 mmol) in 67.5 % yield.  [α]D
20 29.7 (c = 0.2, CHCl3); Rf 0.52 (9:1, 
DCM:MeOH); IR (thin film) 3331, 2960, 2929, 2870, 1735, 1673, 1509, 1368, 
1151 cm-1; 1H NMR (600.1 MHz, CDCl3) δ (ppm): 7.58 (d, J = 8.5 Hz, 1H), 5.24 
(m, 1H), 4.47 (td, J = 8.9, 5.0 Hz, 1H), 3.64 (s, 2H), 3.25 (d, J = 7.5 Hz, 1H), 2.63 
(m, 1H), 2.36 (brs, 1H), 1.62 (m, 1H), 1.56 (d, J = 6.5 Hz, 3H), 1.52 (m, 1H), 1.43 
(s, 9H), 1.19 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.2 Hz, 6H);  13C NMR (150.9 MHz, 
CDCl3) δ (ppm): 173.1, 172.1, 143.8, 114.3, 81.5, 68.3, 50.8, 47.8, 42.7,  41.7, 
27.9, 25.0, 22.9, 21.9, 17.7, 14.5; HRMS (TOF, ES+) C18H33N2O3 [M+H]
+ calc'd 
325.2491, found 325.2491 
 
 
 
(S)-tert-butyl 2-((2R,3R,4Z)-1-((S)-2-benzamido-6-(2,3-bis(tert-
butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-
carboxamido)-4-methylpentanoate (80).  79 (23.7 mg, 0.073 mmol) and 61 
(36.0 mg, 0.073 mmol), in anhydrous DCM (0.3 mL each), were added to a flame 
dried flask under argon via syringe.  Anhydrous DMF (0.3 mL) was added and 
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the solution was cooled to 0 °C.  O-(7-Azabenzotriazol-1-yl)-N,N,N,N-
tetramethyluronium hexafluorophosphate (41.7 mg, 0.111 mmol) was added 
immediately followed by collidine (10.6 µL, 0.080 mmol).  The reaction was 
stirred at 0 °C for 6 hr and then diluted with DCM (4 mL) and washed with H2O (3 
x 2 mL) and filtered through a phase separator.  The crude mixture was 
concentrated in vacuo and then purified by flash chromatography (1:0 to 1:1 
Hex:EtOAc) to yield the product as a crusty foam (47.0 mg, 0.059 mmol) in 80.5 
% yield.  [α]D
20 23.9 (c = 0.2, CHCl3); IR (thin film) 3330, 2964, 2929, 2929, 1722, 
1639, 1154, 1135 cm-1; 1H NMR (600.1 MHz, CDCl3) δ (ppm): 11.47 (brs, 1H), 
8.35 (brs, 1H), 7.82 (m, 2H), 7.48 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.7 Hz, 2H), 
7.11 (d, J = 8.5 Hz, 1H), 6.94 (brs, 1H), 5.44 (m, 1H),  4.83 (q, J = 6.8 Hz, 1H), 
4.49 (d, J = 14.3 Hz, 1H), 4.42 (m, 1H), 4.37 (d, J = 1.4 Hz, 1H), 4.30 (d, J = 14.3 
Hz, 1H), 3.43 (m, 2H), 3.14 (q, J = 7.0 Hz, 1H), 1.93 (m, 1H), 1.86 (m, 1H),  1.67 
(m, 2H), 1.62 (d, J = 6.8 Hz, 3H), 1.59 (m, 1H), 1.52 (m, 4H), 1.48 (s, 9H), 1.47 
(s, 9H), 1.36 (s, 9H), 1.16 (d, J = 7.2 Hz, 3H), 0.82 (d, J = 6.1 Hz, 3H), 0.70 (d, J 
= 6.1 Hz, 3H);  13C NMR (150.9 MHz, CDCl3) δ (ppm): 171.81, 171.76, 169.8, 
167.5, 163.3, 156.1, 153.2, 139.0, 133.3, 131.8, 128.5, 127.3, 118.1, 83.2, 81.2, 
79.5, 66.6, 51.7, 51.2, 47.8, 41.2, 40.9, 40.6, 31.7, 28.9, 28.2, 28.0, 27.9, 24.6, 
22.9, 22.6, 21.8, 21.2, 14.7; HRMS (TOF, ES+) C42H67N6O9 [M+H]
+ calc'd 
799.4970, found 799.4970 
 
 101 
 
 
 
8-epi-Lucentamycin A (81).  80 (38.3 mg, 0.048 mmol) was dissolved in 
anhydrous DCM (0.38 mL) and cooled to 0 °C.  TFA (0.12 mL) was added 
dropwise and the solution was allowed to warm to room temperature over 3 hrs 
and stirred overnight under an argon atmosphere.  MeOH was added to the 
reaction mixture which was then concentrated in vacuo.  More MeOH was added 
and the reaction concentrated again.  Because of the high polarity of the 
compound, the product was purified by reverse phase preparatory HPLC to yield 
the product as a white solid (12.3 mg, 0.023 mmol) in 47.3 % yield.  [α]D
20 28.5 (c 
= 0.2, MeOH); 1H NMR (600.1 MHz, DMSO-d6) δ (ppm): 10.19 (m, 1H), 8.63 (d, J 
= 7.1 Hz, 1H) 8.22 (d, J = 9.0 Hz, 1H), 7.90 (m, 2H), 7.51 (t, J = 7.3 Hz, 1H), 7.44 
(t, J = 7.6 Hz, 2H), 6.95 (m, 2H), 5.26 (m, 1H),  4.69 (d, J = 1.7 Hz, 1H), 4.45 (m, 
1H), 4.16 (d, J = 16.2 Hz, 1H), 4.00 (m, 1H), 3.89 (d, J = 16.5 Hz, 1H), 3.32 (brs, 
2H), 3.05 (m, 1H), 2.93 (m, 1H), 2.62 (m, 1H), 1.65 (m, 1H), 1.55 (m, 7H),  1.47 
(m, 1H), 1.39 (m, 1H), 1.32 (m, 2H) 1.16 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.1 Hz, 
3H), 0.80 (d, J = 6.1 Hz, 3H);  13C NMR (150.9 MHz, DMSO-d6) δ (ppm): 177.0, 
171.3, 170.5, 166.3, 157.6, 140.4, 133.8, 131.3, 128.1, 127.6, 115.0, 66.5, 52.3, 
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51.4, 47.9, 45.1, 41.3, 40.6, 40.0, 30.1, 28.1, 24.9, 23.2, 21.6, 21.2, 14.3; HRMS 
(TOF, ES+) C28H43N6O5 [M+H]
+ calc'd 543.3295, found 543.3295. 
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CHAPTER IV 
 
DEVELOPMENT OF MICROWAVE METHODOLOGY TO 
FACILITATE THE SYNTHESIS OF BMP INHIBITORS 
 
 
Background 
 Bone morphogenetic proteins (BMPs) are soluble proteins that are part of 
the transforming growth factor-β (TGF-β) superfamily.27  They were originally 
discovered for their ability to induce endochondral bone formation,28 and are now 
understood to be a group of morphogenetic signals which coordinate tissue 
architecture throughout the body.29 
 Activating mutations in ALK2 (ACVR1), a BMP type-I receptor, have been 
shown to be the cause of the debilitating and heretofore incurable fibrodysplasia 
ossificans progressiva (FOP).30-32  FOP causes fibrous tissues such as muscles, 
ligaments, and tendons, when damaged, to be become ossified.  This 
progressive heterotopic ossification immobilizes the host and causes death.33  
The discovery of the pyrazolo[1,5-a]pyrimidine, Dorsomorphin (83), has 
immediate therapeutic implications for FOP.  Not only does Dorsomorphin have 
implications for FOP, but Dorsomorphin and its analogue LDN-193189 (84) 
(Figure 8) have also been used to direct differentiation of stem cells and to 
demonstrate the therapeutic potential of targeting BMP signals for anemia and 
hyperossification syndromes in general.34-36 
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Figure 8.  Dorsomorphin (83) and analog LDN-193189 (84) 
 
 Pyrazolo[1,5-a]pyrimidines represent an important  biologically active 
class of nitrogen-containing heterocycles.  Pyrazolo[1,5-a]pyrimidines with aryl 
and/or heteroaryl substituents in the 3- and 6-positions are known ATP-
competitive kinase inhibitors with nanomolar potency for a variety of kinases, 
such as KDR, and can be considered a kinase “privileged structure”.37,38 
 Our laboratory employs an iterative analog library synthesis approach to 
rapidly develop structure-activity-relationships (SAR) and proof of concept 
compounds; however, the known synthetic routes to pyrazolo[1,5-a]pyrimidines, 
such as 83, were inefficient and not ammenable to iterative library synthesis 
(Scheme 11). Classical conditions involve refluxing a 5-amino-4-arylpyrazole 
(87) with a commercially available 2-arylmalondialdehyde (88) in ethanol with 
catalytic acetic acid for 24 hours to deliver pyrazolo[1,5-a]pyrimidine (89) in 40-
60% yield. The starting 5-amino-4-arylpyrazoles (87) were prepared in two steps 
from the corresponding acetonitriles (85) by refluxing in DMF/dimethylacetamide 
(DMA) to afford acrylonitrile (86), followed by treatment with hydrazine in 
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refluxing ethanol to afford 87 in 55-75% yield.  The overall sequence required 
three overnight (72 hours total) reflux reactions.37,38 
 
 
Scheme 11. Classical synthesis of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines 
(89) 
 
 
 As many of the leads identified from HTS campaigns are small 
heterocyclic compounds, our laboratory has devoted significant effort to develop 
efficient protocols for the preparation of diverse heterocyclic templates employing 
microwave-assisted organic synthesis (MAOS).  In recent reports, we have 
described general, high-yielding MAOS protocols for the expedient synthesis of 
1,2,4-triazines (90), imidazoles (91), quinoxalines (92), pyrazinone (93), 5-
amniooxazoles (94), and quinoxalinones (95) from simple starting materials 
(Figure 9).39  Therefore, application of MAOS to develop a general, high-yielding 
and expedient synthesis of pyrazolo[1,5-a]pyrimidines (89)  seemed warranted. 
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Figure 9. Heterocyclic templates accessed by microwave-assisted organic 
synthesis 
 
 
Methodology Development 
 Conventional thermal conditions were quickly adapted and optimized on a 
single-mode microwave synthesizer.   Our initial optimization work was aimed at 
preparing the pyrazolo[1,5-a]pyrimidine (98), which is an intermediate in the 
synthesis of the analogs of Dorsomorphin.  In the snythesis, exposing 
aminopyrazole (96) and malondialdehyde (97) in 5% AcOH/EtOH at 150oC for 10 
minutes afforded pyrazolo[1,5-a]pyrimidine (98) in 85% isolated yield (Scheme 
12).  The product 98 precipitated from solution upon the end-of-run rapid cooling 
to 40oC in the microwave synthesizer, providing analytically pure material by 
filtration.  Further optimization of time and temperature identified 10 minute 
microwave irradiation at 170oC as the optimal reaction conditions to deliver 98 in 
>98% yield on either a 50 mg or 1 g scale. 
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Scheme 12.  Microwave-assisted organic synthesis of pyrazolo[1,5-a]pyrimidine 
(98) 
 
 
 As shown in Table 1, the MAOS conditions proved to be general for the 
reacting malondialdehyde providing C-6 functionalized pyrazolo[1,5-a]pyrimidines 
(89) in excellent isolated yields by simple filtration to afford the acetate salts. 
Neutral products could be obtained by neutralization of the crude reaction with 
concentrated NH4OH and filtration.  Pyridine heterocycles (entries a, b, d and f) 
were tolerated in the pyrazole component 87, as were unsubstituted phenyl 
congeners (entries 3 and 6). A 5-amino-4-bromopyrazole derivative 87 (where 
Ar1=Br) afforded the desired product 89, but in low yield.  This was unfortunate 
as the bromo analogue offered opportunities for further analogue libraries 
through MAOS-Suzuki couplings. With respect to the malonoaldehyde 
component 88, both aryl and heteroaryl congeners provided uniformly good 
results.  Thus, our new MAOS protocol (10 minutes, 170oC) afforded the desired 
products 89 in >90% conversion. 
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Table 1.  Representative pyrazolo[1,5-a]pyrimidines (89a-89f) 
 
 With a general MAOS protocol for the expedient synthesis of 3,6-
disubstituted pyrazolo[1,5-a]pyrimidines 89, attention now focused on improving 
the synthesis of the requisite starting 5-amino-4-arylpyrazoles 87.  Few of these 
analogs are commercially available, and those that can be purchased are 
expensive (~$100/g).  In order to improve the synthesis, we again employed 
MAOS.  Nitrile (99) was heated at 150oC in DMF/DMA to afford complete 
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conversion to acrylonitrile (100) in 10 minutes, as judged by analytical LC/MS.  
To the same microwave vial, was added hydrazine via syringe, and the vial was 
heated again under microwave irradiation to 140oC for 10 minutes to deliver the 
desired 5-amino-4-pyridylpyrazole (96) in 85% isolated yield (Scheme 13).  This 
represents a significant improvement over the conventional thermal protocol that 
required 48 hours of reaction time with only a 55-75% yield.  Thus, a reaction 
sequence that required >72 hours and provided 40-60% yield has been 
optimized to require only 30 minutes total reaction time (for three steps) with 
overall yields in excess of 80%. 
 
 
Scheme 13.  Microwave-assisted organic synthesis protocol for the synthesis of 
5-amino-4-pyridylpyrazole (96) 
 
 
Synthesis of Analog Library 
The desire for selective potent BMP inhibitors and the pyrazolo[1,5-
a]pyrimidine lead compound Dorsomorphin (83) led us to initiate a medicinal 
chemistry program using our methodology.  Employing MAOS, a small library of 
14 compounds was afforded by first deprotecting the methyl ether of 98 by 
adapting thermal conditions for use on a single-mode microwave synthesizer to 
yield the phenol (101) (Scheme 14).  Phenol 101 was then alkylated using 
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microwave procedures developed in our lab to yield pyrazolo[1,5-a]pyrimidine 
(102). 
 
 
Scheme 14.  Synthesis of Dorsomorphin analog library 
 
Fourteeen different halides were used in the alkylations consisting of alkyl 
chlorides, alkyl bromides, α-bromo ketones, and α-bromo esters (Figure 10).  
Use of the microwave for the deprotection of the methyl ether and the alkylations 
allowed for a significant decrease in the reaction times and an increase in the 
yield for the alkylations as compared to conventional heating.38 
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Figure 10.  Library of halides used for diversification of Dorsomorphin 
 
Biological Evaluation of Analogs 
 When BMP signaling is interrupted in zebrafish embryos a dorsalization of 
the embryonic axis occurs, as seen below, compared to normal zebrafish 
embryonic axis development (Figure 11).  Dr. Charles Hong tests for BMP 
inhibition, and KDR inhibition on zebrafish. 
 
 
Figure 11.  Zebrafish embryo with normal axis and dorsalized axis 
 
 Inhibition of intersomitic (IS) angiogenic sprouting in zebrafish can be used 
as an in vivo assay for KDR inhibitory activity.  This is performed by dosing 
transgenic fish expressing green fluorescent protein in endothelial cells two days 
after fertilization (Figure 12). 
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Figure 12. Inhibition of IS sprouting in zebrafish expressing green fluorescent 
protein in endothelial cells by inhibiting KDR 
 
 
 The compounds given to Dr. Hong were first tested in the zebrafish to 
determine if they were BMP inhibitors.  The compounds that inhibited BMP, and 
were not lethal to the zebrafish after 48 hours, were then tested to determine if 
they inhibited KDR (Table 2). 
  
Control KDR inhibitor 50M
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R = Efficacy for BMP Inhibition Lethal IS Angiogenic Sprouting 
H 2 μM yes not determined 
CH3 >50 μM no not determined 
 
5-10 μM no somewhat abnormal at 20 μM 
 
>50 μM no not determined 
 
2 μM yes not determined 
 
>50 μM no not determined 
 
5-10 μM no somewhat abnormal at 20 μM 
 <5 μM yes not determined 
 10 μM no normal at 50 μM 
 
5 μM no somewhat abnormal at 50 μM 
 
<5 μM yes not determined 
 
5-10 μM no somewhat abnormal at 50 μM 
 
5-10 μM no somewhat abnormal at 20 μM 
 
2-5 μM no all abnormal at 20 μM 
Table 2.  Biological evaluation of Dorsomorphin analogs 
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 Compounds of special interest are entries 9 and 10 of Table 2; the butyl 
ether (103) and cyclopropylmethyl (104) ether, respectively (Figure 13).  
Compound 103 inhibited BMP at 10 µM, was not lethal, and showed no effect on 
KDR at 50 µM, while 104 inhibited BMP at 5 µM, was not lethal, and showed a 
mild inhibition of KDR as evident by somewhat abnormal IS angiogenic sprouting 
in zebrafish at 50 µM.  Both of these compounds are improvements on the 
original lead of Dorsomorphin 83, which inhibited BMP at 5 µM, was not lethal, 
and showed a mild inhibition of KDR as evident by somewhat abnormal IS 
angiogenic sprouting in zebrafish at 20 µM.  This led to the determination that an 
aliphatic group in the 6-position is important for BMP selectivity. 
 
 
Figure 13.  Compounds of special interest 
 
 This work was carried on by others and eventually both a potent and very 
selective inhibitor of BMP signaling, DMH1 (105), and a potent, selective VEGFR 
inhibitor, DMH4 (106) were developed (Figure 14)40.  Using in vitro kinase 
assays, compound 105 had an IC50 of 107.9 nM at ALK2 (BMPR-I) and showed 
no inhibition of the closely related ALK5 (TGFβR-I), AMPK, KDR (VEGFR2), or 
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PDGFRβ.  When 106 was tested in the same assays it showed selectivity for 
VEGFR with an IC50 of 161 nM at KDR (VEGFR2), IC50s of 3.6 μM and 8.0 μM at 
ALK2 (BMPR-I) and AMPK, respectively, and no inhibition of ALK5 (TGFβR-I), 
while not tested on PDGFRβ.  DMH1 (105) is not only potent, but also much 
selective than the lead compound Dorsomorphin (83) and other reported BMP 
inhibitors such as LDN-193189 (84) (Table 3). 
 
 
Figure 14. DMH1 (105) and DMH4 (106) selective and potent inhibitors of BMP 
and VEGF respectively 
 
 
 
Table 3. Effects of Dorsomorphin and analogues on in vitro kinase assays 
 
Conclusions 
 Thus, microwave assisted organic chemistry was applied to the synthesis 
of pyrazolo[1,5-a]pyrimidines.  By doing this, a reaction sequence that required 
IC50 (nM)
ALK2 
(BMPR-I)
ALK5 
(TGFβR-I)
AMPK
KDR 
(VEGFR2)
PDGFRβ
DMH1 (105) 107.9 >30000 >30000 >30000 >30000
DMH4 (106) 3558.0 >30000 8038.0 161.0 n.t.
DM (83) 148.1 >30000 234.6 25.1 n.t.
LDN-193189 (84) 40.7 565.0 1122.0 214.7 n.t.
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>72 hours and provided 40-60% yield has been optimized to require only 30 
minutes total reaction time (for three steps) with overall yields in excess of 80%.  
This new methodology was then used in the synthesis of a small library of 
Dorsomorphin analogs which were evaluated for their activity against BMP and 
VEGF.  With the first library, a compound was found that was more selective and 
potent than the lead compound 83.  This work was continued on to develop the 
first selective potent BMP inhibitor, DMH1 (105).  With this compound in hand 
other heterocycles can be explored that keep the substitutions in the 3 and 6 
positions of the pyrazolo[1,5-a]pyrimidines in the same physical space while 
varying the heterocycle core.  This strategy could provide some room in the 
intellectual property space, which in turn would allow the development of a BMP 
inhibitor into a drug.  A drug that inhibits BMP could be a life altering and even a 
life saving therapy for patients with FOP. 
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Experimental Section 
General Experimental 
All 1H and 13C NMR spectra were recorded on 300 MHz, 400 MHz or 500 MHz 
instruments. Chemical shifts are reported in ppmrelative to residual solvent 
peaks as an internal standard set to δ 7.26 and δ 77.0 (CDCl3). Data are 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q =quartet, br = broad, m = multiplet), integration, coupling constant (Hz).   2-
Dimensional NMR spectra (NOESY and COSY) were obtained on a 500 
spectrometer (operating at 500.134 MHz for 1H and 124.996 MHz for 13C).  IR 
spectra were recorded as thin films and are reported in wavenumbers (cm-1). 
Low resolution mass spectra were obtained on an analytical LCMS with 
electrospray ionization. High resolution mass spectra were recorded on a Qtof-
API-US system.  The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference. Analytical thin layer chromatography was 
performed on 250 μM silica gel 60 F254 plates. Visualization was accomplished 
with UV light, and/or the use of ninhydrin, anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on 
silica gel was performed using Silica Gel 60 (230- 400 mesh) from Sorbent 
Technologies. Analytical HPLC was performed on an analytical LCMS with UV 
detection at 214 nm and 254 nm along with ELSD detection. Chiral HPLC was 
performed on an analytical HPLC utilizing a Chiracel OD, OJ or Chiralpak AD 
columns (4.6 mm x 25 cm). Solvents for extraction, washing and chromatography 
were HPLC grade. All reagents were purchased and were used without 
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purification. All polymer-supported reagents were purchased. Flame-dried (under 
vacuum) glassware was used for all reactions. All reagents and solvents were 
commercial grade and purified prior to use when necessary. Mass spectra were 
obtained on a Q-TOF API-US mass spectrometer to acquire high-resolution 
mass spectrometry (HRMS) data. 
 
Experimental: 
 
 
 
6-(4-methoxy)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine (98).  The 
experimental for 98 is the general procedure for pyrazolo[1,5-a]pyrimidines (89).  
Pyrazole 96 (664 mg, 4mmol) is dissolved in 3.5 mL of 5% AcOH/EtOH and then 
2-(4-methoxyphenyl)malondialdehyde (97) (712 mg, 4 mmol) was added.  The 
microwave reaction vessel was sealed and irradiated with microwaves to 170oC 
for 10 minutes.  Upon rapid cooling to 40oC, the product precipitated from 
solution.  NH4OH was added to neutralize the solution, and the product collected 
by filtration and washed with water to afford 98 as a white solid (1.18 g, 98%).  1H 
NMR (CDCl3, 400 MHz): δ (ppm): 8.87 (d, J=2 Hz, 1H), 8.82 (d, J=2 Hz, 1H), 
8.64 (d, J=5.6 Hz, 2H), 8.53 (s, 1H), 8.01 (d, J=6 Hz, 2H), 7.54 (d, J=8.8 Hz, 2H), 
 121 
 
7.07 (d, J=8.8 Hz, 2H), 3.88 (s, 3H); );  13C NMR (CDCl3, 100 MHz): δ (ppm): 
160, 150.3, 150.1, 144.4, 143.2, 139.6, 131.6, 128, 125.7, 123.2, 120.2, 115, 
107.7, 55.4; LCMS, single peak, 2.27 min, m/e, 303.1 (M+1). 
 
 
 
4-(pyridin-4-yl)-1H-pyrazol-5-amine (96).  The experimental for 96 is the 
general procedure for the aminopyrazoles 87.  2-(pyridin-4-yl)acetonitrile 99 (565 
mg, 5 mmol) was disolved in a 3 mL solution of DMA:DMF:PhCF3 (1:1:2).  The 5 
mL microwave reaction vessel  was heated to 150oC for 10 minutes by 
microwave irradiation.   LCMS (single peak, 1.1 min, m/e, 174.1 (M+1)) indicated 
that all 99 was consumed affording acrylonitrile 100.  Hydrazine (160 µL, 5.1 
mmol) was then added via syringe and the vial heated to 140oC for 10 minutes.  
Aqueous work-up, followed by preparartive LCMS afforded 680 mg (85%) of 4-
(pyridin-4-yl)-1H-pyrazol-5-amine, 96 as a purple solid. 1H NMR (d6-DMSO, 400 
MHz): δ (ppm): 8.38 (d, J=6 Hz, 2H), 7.84 (s, 1H), 7.47 (d, J=6 Hz, 2H), 5.14 (bs, 
2H);   13C NMR (d6-DMSO, 100 MHz): δ (ppm) 154, 149.5, 141.4, 132, 124, 119; 
LCMS, single peak, 0.39 min, m/e, 161.1 (M+1). 
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6-(4-phenol)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine (101).  98 (1.5g, 
5mmol) was disolved in a 20 mL solution of 48% HBr:Acetic acid (1:1) in a 20 mL 
microwave reaction vessel which was then heated to 180oC for 10 minutes by 
microwave irradiation.  Upon cooling the phenol 101 precipatated out of soultion 
and was filtered to yield the HBr salt as a yellow solid (1.83g, quanitative yield).  
%).  1H NMR (CDCl3, 400 MHz): δ (ppm): 9.84 (brs, 1H), 9.61 (d, J=2.4 Hz, 1H), 
9.25 (s, 1H), 8.83 (d, J=6.8 Hz, 2H), 8.71 (d, J=6.8 Hz, 2H), 7.74 (d, J=8.8 Hz, 
2H), 6.93 (d, J=8.8 Hz, 2H);  13C NMR (CDCl3, 100 MHz): δ (ppm): 158.4, 152.7, 
148.4, 145.8, 144.9, 141.6, 133.3, 128.5, 124.1, 123.0, 120.6, 116.1, 104.2; 
LCMS, single peak, 1.95 min, m/e, 289.1 (M+1). 
 
 
 
Alkyl ethers (102).  General procedure:  101 (50mg, 0.14mmol) was dissloved in 
5 mL of DMF in a 5 mL microwave reaction vessel.  KI (69.7mg, 0.42mmol), 
 123 
 
Cs2CO3 (182mg, 0.56mmol) and the alkyl halide (0.42mmol) were added the vial 
sealed and irradiated with microwaves to 160oC for 60 minutes.  Upon cooling 
the mixture was filtered, the eluent dried down on the sample concentrater, and 
purified by preparartive LCMS to afford 102 in >90% purity. 
 
  
  
 
 
 
 
 
 
 
 
APPENDIX 
NMR SPECTRA 
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